https://www.pharmaceutical-technology.com/data-insights/yimmugo-biotest-primary-immune-deficiency-pid-likelihood-of-approval/ 2024-12-29T17:04:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/temuterkib-eli-lilly-and-co-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2024-12-29T17:04:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/temuterkib-eli-lilly-and-co-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2024-12-29T17:04:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/disitamab-vedotin-pfizer-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2024-12-29T17:04:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/btxa-51-edgewood-oncology-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2024-12-29T17:04:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tovinontrine-cardurion-pharmaceuticals-systolic-heart-failure-likelihood-of-approval-2/ 2024-07-04T18:03:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/btxa-51-edgewood-oncology-solid-tumor-likelihood-of-approval/ 2024-12-29T17:04:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cx-904-cytomx-therapeutics-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2024-12-29T17:04:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cx-904-cytomx-therapeutics-metastatic-adenocarcinoma-of-the-pancreas-likelihood-of-approval/ 2024-12-29T17:04:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cx-904-cytomx-therapeutics-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-29T17:04:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cx-904-cytomx-therapeutics-esophageal-cancer-likelihood-of-approval/ 2024-12-29T17:04:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/otq-923-novartis-sickle-cell-disease-likelihood-of-approval/ 2024-12-29T17:04:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cx-904-cytomx-therapeutics-gastric-cancer-likelihood-of-approval/ 2024-12-29T17:04:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/afm-24i-affimed-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-29T17:04:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vusolimogene-oderparepvec-replimune-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-12-29T17:04:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bevacizumab-biosimilar-bio-thera-solutions-recurrent-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-12-29T17:04:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/olp-1002-olipass-osteoarthritis-pain-likelihood-of-approval/ 2024-07-04T17:59:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/surzebiclimab-beigene-solid-tumor-likelihood-of-approval/ 2024-12-29T17:04:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abgn-268-altrubio-psoriatic-arthritis-likelihood-of-approval/ 2024-12-29T17:04:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/efineptakin-alfa-neoimmunetech-colorectal-cancer-likelihood-of-approval/ 2024-12-29T17:04:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/regn-6569-regeneron-pharmaceuticals-colorectal-cancer-likelihood-of-approval/ 2024-07-04T17:58:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/patritumab-deruxtecan-daiichi-sankyo-esophageal-squamous-cell-carcinoma-escc-likelihood-of-approval/ 2024-12-29T17:04:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/belrestotug-iteos-therapeutics-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-29T17:04:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/patritumab-deruxtecan-daiichi-sankyo-epithelial-ovarian-cancer-likelihood-of-approval/ 2024-12-29T17:03:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/patritumab-deruxtecan-daiichi-sankyo-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2024-12-29T17:03:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/patritumab-deruxtecan-daiichi-sankyo-acral-lentiginous-melanoma-likelihood-of-approval/ 2024-12-29T17:03:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/patritumab-deruxtecan-daiichi-sankyo-peritoneal-cancer-likelihood-of-approval/ 2024-12-29T17:03:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/patritumab-deruxtecan-daiichi-sankyo-endometrial-cancer-likelihood-of-approval/ 2024-12-29T17:03:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/patritumab-deruxtecan-daiichi-sankyo-fallopian-tube-cancer-likelihood-of-approval/ 2024-12-29T17:03:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/naporafenib-erasca-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-29T17:03:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/patritumab-deruxtecan-daiichi-sankyo-cervical-cancer-likelihood-of-approval/ 2024-12-29T17:03:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/repotrectinib-bristol-myers-squibb-liver-failure-hepatic-insufficiency-likelihood-of-approval/ 2024-12-29T17:03:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/evalstotug-bioatla-melanoma-likelihood-of-approval/ 2024-12-29T17:03:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cd19-t-hank-immunitybio-b-cell-non-hodgkin-lymphoma-likelihood-of-approval/ 2024-12-29T17:03:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/igv-001-imvax-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-07-04T17:54:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/serplulimab-shanghai-henlius-biotech-gastric-cancer-likelihood-of-approval/ 2024-12-29T17:03:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/serplulimab-shanghai-henlius-biotech-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval/ 2024-12-29T17:03:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sapablursen-sodium-ionis-pharmaceuticals-polycythemia-vera-likelihood-of-approval/ 2024-07-04T17:53:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sasanlimab-pfizer-muscle-invasive-bladder-cancer-mibc-likelihood-of-approval/ 2024-07-04T17:53:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vopratelimab-concentra-biosciences-solid-tumor-likelihood-of-approval/ 2024-09-09T07:12:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vopratelimab-concentra-biosciences-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-09-09T07:12:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sintilimab-innovent-biologics-colorectal-cancer-likelihood-of-approval/ 2024-12-29T17:03:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sintilimab-innovent-biologics-pleomorphic-liposarcoma-likelihood-of-approval/ 2024-12-29T17:03:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mcla-145-merus-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-12-29T17:03:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mcla-145-merus-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-29T17:03:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mcla-145-merus-solid-tumor-likelihood-of-approval/ 2024-12-29T17:03:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mcla-145-merus-anal-cancer-likelihood-of-approval/ 2024-12-29T17:03:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mcla-145-merus-gastric-cancer-likelihood-of-approval/ 2024-12-29T17:02:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mcla-145-merus-sarcomas-likelihood-of-approval/ 2024-12-29T17:03:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mcla-145-merus-cervical-cancer-likelihood-of-approval/ 2024-12-29T17:02:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mcla-145-merus-pancreatic-cancer-likelihood-of-approval/ 2024-12-29T17:02:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cemiplimab-regeneron-pharmaceuticals-colon-cancer-likelihood-of-approval/ 2024-12-29T17:02:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mcla-145-merus-colorectal-cancer-likelihood-of-approval/ 2024-12-29T17:02:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brepocitinib-tosylate-priovant-therapeutics-panuveitis-likelihood-of-approval/ 2024-12-29T17:02:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pemigatinib-incyte-squamous-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-07-04T17:49:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vonafexor-enyo-pharma-alport-syndrome-likelihood-of-approval/ 2024-07-04T17:48:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ritlecitinib-pfizer-crohn-s-disease-regional-enteritis-likelihood-of-approval/ 2024-12-29T17:02:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brensocatib-insmed-bronchiectasis-likelihood-of-approval/ 2024-12-29T17:02:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/danicopan-alexion-pharmaceuticals-atypical-hemolytic-uremic-syndrome-nondiarrhea-associated-hemolytic-uremic-syndrome-likelihood-of-approval/ 2024-12-29T17:02:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aur-109-orion-pulmonary-fibrosis-likelihood-of-approval/ 2024-12-29T17:02:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aur-109-orion-liver-cancer-likelihood-of-approval/ 2024-12-29T17:02:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aur-109-orion-kidney-cancer-renal-cell-cancer-likelihood-of-approval/ 2024-12-29T17:02:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aur-109-orion-lung-cancer-likelihood-of-approval/ 2024-12-29T17:02:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aur-109-orion-ovarian-cancer-likelihood-of-approval/ 2024-12-29T17:02:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/luveltamab-tazevibulin-sutro-biopharma-peritoneal-tumor-likelihood-of-approval/ 2024-12-29T17:02:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aur-109-orion-breast-cancer-likelihood-of-approval/ 2024-12-29T17:02:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sirolimus-biodexa-pharmaceuticals-familial-adenomatous-polyposis-likelihood-of-approval/ 2024-12-29T17:02:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/donafenib-tosylate-suzhou-zelgen-biopharmaceutical-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2024-09-09T07:11:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/axitinib-clearside-biomedical-wet-neovascular-exudative-macular-degeneration-likelihood-of-approval/ 2024-07-04T17:44:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/celgosivir-hydrochloride-60-degrees-pharmaceuticals-respiratory-syncytial-virus-rsv-infections-likelihood-of-approval/ 2024-07-04T17:44:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/donafenib-tosylate-suzhou-zelgen-biopharmaceutical-hepatocellular-carcinoma-likelihood-of-approval/ 2024-09-09T07:11:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/henagliflozin-proline-jiangsu-hengrui-medicine-chronic-kidney-disease-chronic-renal-failure-likelihood-of-approval/ 2024-07-04T17:43:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pariglasgene-brecaparvovec-ultragenyx-pharmaceutical-glycogen-storage-disease-1a-likelihood-of-approval/ 2024-12-29T17:02:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/seltorexant-johnson-johnson-insomnia-likelihood-of-approval/ 2024-12-29T17:02:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/seltorexant-johnson-johnson-major-depressive-disorder-likelihood-of-approval/ 2024-12-29T17:02:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cm-101-chemomab-therapeutics-systemic-sclerosis-scleroderma-likelihood-of-approval/ 2024-07-04T17:41:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/amlitelimab-sanofi-systemic-sclerosis-scleroderma-likelihood-of-approval/ 2024-12-29T17:01:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/avapritinib-blueprint-medicines-metastatic-colorectal-cancer-likelihood-of-approval/ 2024-12-29T17:01:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zl-1102-zai-lab-plaque-psoriasis-psoriasis-vulgaris-likelihood-of-approval/ 2024-12-29T17:01:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/avapritinib-blueprint-medicines-metastatic-breast-cancer-likelihood-of-approval/ 2024-12-29T17:01:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/avapritinib-blueprint-medicines-metastatic-lung-cancer-likelihood-of-approval/ 2024-12-29T17:01:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/entrectinib-f-hoffmann-la-roche-neuroblastoma-likelihood-of-approval/ 2024-12-29T17:01:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fenebrutinib-genentech-usa-primary-progressive-multiple-sclerosis-ppms-likelihood-of-approval/ 2024-09-09T07:11:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fs-222-f-star-therapeutics-malignant-mesothelioma-likelihood-of-approval/ 2024-12-29T17:01:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fs-222-f-star-therapeutics-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-12-29T17:01:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fs-222-f-star-therapeutics-colorectal-cancer-likelihood-of-approval/ 2024-12-29T17:01:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fs-222-f-star-therapeutics-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-29T17:01:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sx-682-syntrix-pharmaceuticals-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2024-12-29T17:01:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fs-222-f-star-therapeutics-ovarian-cancer-likelihood-of-approval/ 2024-12-29T17:01:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/empasiprubart-argenx-multifocal-motor-neuropathy-likelihood-of-approval/ 2024-12-29T17:01:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ivosidenib-les-laboratoires-servier-chronic-myelomonocytic-leukemia-cmml-likelihood-of-approval/ 2024-12-29T17:01:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bhv-7000-biohaven-bipolar-i-disorder-likelihood-of-approval/ 2024-12-29T17:01:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ritivixibat-ipsen-primary-sclerosing-cholangitis-likelihood-of-approval/ 2024-12-29T17:01:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bhv-7000-biohaven-major-depressive-disorder-likelihood-of-approval/ 2024-12-29T17:01:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mavacamten-bristol-myers-squibb-diastolic-heart-failure-hfpef-likelihood-of-approval/ 2024-12-29T17:01:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pacmilimab-cytomx-therapeutics-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2024-12-29T17:01:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pacmilimab-cytomx-therapeutics-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-12-29T17:01:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lifirafenib-maleate-beigene-solid-tumor-likelihood-of-approval/ 2024-12-29T17:00:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pacmilimab-cytomx-therapeutics-metastatic-breast-cancer-likelihood-of-approval-2/ 2024-12-29T17:00:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ttx-333-temple-therapeutics-scar-likelihood-of-approval/ 2024-07-04T17:33:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gma-301-gmax-biopharm-pulmonary-arterial-hypertension-likelihood-of-approval/ 2024-12-29T17:00:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/berzosertib-merck-neuroendocrine-cancer-likelihood-of-approval/ 2024-07-04T17:33:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/amivantamab-johnson-johnson-solid-tumor-likelihood-of-approval/ 2024-12-29T17:00:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/avelumab-merck-squamous-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-29T17:00:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/indv-2000-indivior-opium-opioid-addiction-likelihood-of-approval/ 2024-12-29T17:00:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/intestinal-schistosomiasis-vaccine-quratis-intestinal-schistosomiasis-likelihood-of-approval/ 2024-07-04T17:31:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nerandomilast-boehringer-ingelheim-international-systemic-sclerosis-scleroderma-likelihood-of-approval/ 2024-12-29T17:00:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sodium-dichloroacetate-saol-therapeutics-neurometabolic-disease-likelihood-of-approval/ 2024-12-29T17:00:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sacituzumab-govitecan-gilead-sciences-squamous-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-29T17:00:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/inva-8001-invea-therapeutics-atopic-dermatitis-atopic-eczema-likelihood-of-approval/ 2024-09-09T07:10:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/protheracytes-cellprothera-myocardial-infarction-likelihood-of-approval/ 2024-07-04T17:29:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sacituzumab-govitecan-gilead-sciences-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2024-12-29T17:00:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/paxalisib-kazia-therapeutics-human-epidermal-growth-factor-receptor-2-positive-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2024-12-29T17:00:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/somatropin-pegol-la-changchun-genescience-pharmaceutical-female-infertility-likelihood-of-approval/ 2024-12-29T17:00:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/idasanutlin-f-hoffmann-la-roche-neuroblastoma-likelihood-of-approval/ 2024-12-29T17:00:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/spn-817-supernus-pharmaceuticals-epilepsy-likelihood-of-approval/ 2024-07-04T17:27:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/emactuzumab-synox-therapeutics-tenosynovial-giant-cell-tumor-likelihood-of-approval/ 2024-12-29T17:00:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/idasanutlin-f-hoffmann-la-roche-solid-tumor-likelihood-of-approval/ 2024-12-29T17:00:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atezolizumab-f-hoffmann-la-roche-urethral-cancer-likelihood-of-approval/ 2024-12-29T17:00:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/iopofosine-i-131-cellectar-biosciences-recurrent-head-and-neck-squamous-cell-carcinoma-likelihood-of-approval/ 2024-12-29T17:00:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atezolizumab-f-hoffmann-la-roche-metastatic-breast-cancer-likelihood-of-approval/ 2024-12-29T17:00:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atezolizumab-f-hoffmann-la-roche-endometrial-cancer-likelihood-of-approval/ 2024-12-29T17:00:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bapotulimab-bayer-solid-tumor-likelihood-of-approval/ 2024-07-04T17:25:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bapotulimab-bayer-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2024-07-04T17:25:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/al-8326-advenchen-laboratories-solid-tumor-likelihood-of-approval/ 2024-09-09T07:10:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/al-8326-advenchen-laboratories-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-09-09T07:10:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/al-8326-advenchen-laboratories-head-and-neck-cancer-likelihood-of-approval/ 2024-09-09T07:09:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/al-8326-advenchen-laboratories-pancreatic-cancer-likelihood-of-approval/ 2024-09-09T07:10:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/al-8326-advenchen-laboratories-colon-cancer-likelihood-of-approval/ 2024-09-09T07:09:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/al-8326-advenchen-laboratories-liver-cancer-likelihood-of-approval/ 2024-09-09T07:09:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/al-8326-advenchen-laboratories-prostate-cancer-likelihood-of-approval/ 2024-09-09T07:09:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/al-8326-advenchen-laboratories-cervical-cancer-likelihood-of-approval/ 2024-09-09T07:09:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/al-8326-advenchen-laboratories-breast-cancer-likelihood-of-approval-2/ 2024-09-09T07:09:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/al-8326-advenchen-laboratories-ovarian-cancer-likelihood-of-approval/ 2024-09-09T07:09:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bimagrumab-eli-lilly-and-co-obesity-likelihood-of-approval/ 2024-12-29T16:59:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dostarlimab-gsk-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2024-12-29T16:59:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/uncategorized/al-8326-advenchen-laboratories-breast-cancer-likelihood-of-approval/ 2024-07-04T17:16:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sanguinate-prolong-pharmaceuticals-acute-ischemic-stroke-likelihood-of-approval/ 2024-07-04T17:16:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/famitinib-jiangsu-hengrui-medicine-follicular-thyroid-cancer-likelihood-of-approval/ 2024-09-09T07:09:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/peltopepimut-s-isa-pharmaceuticals-cervical-cancer-likelihood-of-approval/ 2024-07-04T17:16:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rz-402-rezolute-diabetic-macular-edema-likelihood-of-approval/ 2024-07-04T17:15:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pembrolizumab-merck-transitional-cell-cancer-urothelial-cell-cancer-likelihood-of-approval/ 2024-12-29T16:59:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/camoteskimab-apollo-therapeutics-atopic-dermatitis-atopic-eczema-likelihood-of-approval/ 2024-07-04T17:14:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/deferiprone-chiesi-farmaceutici-human-immunodeficiency-virus-hiv-infections-aids-likelihood-of-approval/ 2024-07-04T17:13:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/condoliase-ferring-international-center-lumbar-hernia-bleichner-s-hernia-likelihood-of-approval/ 2024-07-04T17:13:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pembrolizumab-merck-colorectal-cancer-likelihood-of-approval/ 2024-12-29T16:59:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/conbercept-chengdu-kanghong-pharmaceuticals-group-retinoblastoma-likelihood-of-approval/ 2024-12-29T16:59:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azemiglitazone-cirius-therapeutics-metabolic-dysfunction-associated-steatohepatitis-mash-likelihood-of-approval/ 2024-07-04T17:12:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nogapendekin-alfa-immunitybio-solid-tumor-likelihood-of-approval/ 2024-12-29T16:59:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nogapendekin-alfa-immunitybio-b-cell-non-hodgkin-lymphoma-likelihood-of-approval/ 2024-12-29T16:59:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nogapendekin-alfa-immunitybio-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2024-12-29T16:59:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/amb-051-ammax-bio-tenosynovial-giant-cell-tumor-likelihood-of-approval/ 2024-12-29T16:59:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eniluracil-processa-pharmaceuticals-metastatic-colorectal-cancer-likelihood-of-approval/ 2024-12-29T16:59:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ribociclib-succinate-novartis-neuroblastoma-likelihood-of-approval/ 2024-12-29T16:59:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/neflamapimod-cervomed-lewy-body-dementia-likelihood-of-approval/ 2024-12-29T16:59:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bevacizumab-f-hoffmann-la-roche-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2024-12-29T16:59:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bevacizumab-f-hoffmann-la-roche-neuroblastoma-likelihood-of-approval/ 2024-12-29T16:59:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ipatasertib-genentech-usa-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2024-12-29T16:59:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nimotuzumab-innomab-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2024-12-29T16:59:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ipatasertib-genentech-usa-oropharyngeal-cancer-likelihood-of-approval/ 2024-12-29T16:59:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ipatasertib-genentech-usa-paranasal-sinus-and-nasal-cavity-cancer-likelihood-of-approval/ 2024-12-29T16:59:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ipatasertib-genentech-usa-oral-cavity-mouth-cancer-likelihood-of-approval/ 2024-12-29T16:59:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ipatasertib-genentech-usa-hypopharyngeal-cancer-likelihood-of-approval/ 2024-12-29T16:58:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ipatasertib-genentech-usa-laryngeal-cancer-likelihood-of-approval/ 2024-12-29T16:59:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/padeliporfin-potassium-impact-biotech-transitional-cell-cancer-urothelial-cell-cancer-likelihood-of-approval/ 2024-12-29T16:58:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/padeliporfin-potassium-impact-biotech-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2024-12-29T16:58:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ensituximab-precision-biologics-solid-tumor-likelihood-of-approval/ 2024-07-04T17:07:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zolbetuximab-astellas-pharma-gastric-cancer-likelihood-of-approval/ 2024-12-29T16:58:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zolbetuximab-astellas-pharma-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval/ 2024-12-29T16:58:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nemonoxacin-taigen-biotechnology-urinary-tract-infections-likelihood-of-approval/ 2024-12-29T16:58:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xevinapant-merck-nasopharyngeal-cancer-likelihood-of-approval/ 2024-12-29T16:58:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rxdx-105-f-hoffmann-la-roche-ovarian-cancer-likelihood-of-approval/ 2024-07-04T17:05:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rxdx-105-f-hoffmann-la-roche-solid-tumor-likelihood-of-approval/ 2024-07-04T17:05:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/inebilizumab-amgen-immunoglobulin-g4-related-disease-igg4-rd-likelihood-of-approval/ 2024-12-29T16:58:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azeliragon-cantex-pharmaceuticals-pneumonia-likelihood-of-approval/ 2024-12-29T16:58:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/felzartamab-morphosys-systemic-lupus-erythematosus-likelihood-of-approval/ 2024-12-29T16:58:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pritelivir-mesylate-aicuris-anti-infective-cures-genital-herpes-likelihood-of-approval/ 2024-12-29T16:58:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pritelivir-mesylate-aicuris-anti-infective-cures-herpes-labialis-oral-herpes-likelihood-of-approval/ 2024-12-29T16:58:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/catequentinib-hydrochloride-advenchen-laboratories-solid-tumor-likelihood-of-approval/ 2024-12-29T16:58:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bpc-2-meabco-prostate-cancer-likelihood-of-approval/ 2024-07-04T16:58:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pelareorep-oncolytics-biotech-refractory-multiple-myeloma-likelihood-of-approval/ 2024-12-29T16:58:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/catequentinib-hydrochloride-advenchen-laboratories-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-29T16:58:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pixatimod-zucero-therapeutics-metastatic-melanoma-likelihood-of-approval/ 2024-12-29T16:54:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pixatimod-zucero-therapeutics-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-29T16:54:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pixatimod-zucero-therapeutics-metastatic-colorectal-cancer-likelihood-of-approval/ 2024-12-29T16:54:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/momelotinib-dihydrochloride-gsk-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2024-12-29T16:54:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/momelotinib-dihydrochloride-gsk-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2024-12-29T16:54:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vemurafenib-f-hoffmann-la-roche-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2024-12-29T16:54:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vemurafenib-f-hoffmann-la-roche-follicular-thyroid-cancer-likelihood-of-approval/ 2024-12-29T16:54:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/paclitaxel-samyang-biopharmaceuticals-skin-cancer-likelihood-of-approval/ 2024-07-04T16:53:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/paclitaxel-samyang-biopharmaceuticals-oral-cancer-likelihood-of-approval/ 2024-07-04T16:53:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/paclitaxel-samyang-biopharmaceuticals-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2024-07-04T16:53:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/probenecid-sulopenem-etzadroxil-iterum-therapeutics-urinary-tract-infections-likelihood-of-approval/ 2024-12-29T16:54:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ponesimod-vanda-pharmaceuticals-plaque-psoriasis-psoriasis-vulgaris-likelihood-of-approval/ 2024-12-29T16:54:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/paclitaxel-samyang-biopharmaceuticals-laryngeal-cancer-likelihood-of-approval/ 2024-07-04T16:52:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/olaparib-astrazeneca-neuroblastoma-likelihood-of-approval/ 2024-12-29T16:54:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/olaparib-astrazeneca-soft-tissue-sarcoma-likelihood-of-approval/ 2024-12-29T16:54:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cobimetinib-fumarate-f-hoffmann-la-roche-neuroblastoma-likelihood-of-approval/ 2024-12-29T16:54:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/olaparib-astrazeneca-glioma-likelihood-of-approval/ 2024-12-29T16:54:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tisotumab-vedotin-genmab-recurrent-head-and-neck-squamous-cell-carcinoma-likelihood-of-approval/ 2024-09-09T07:08:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/olaparib-astrazeneca-non-hodgkin-lymphoma-likelihood-of-approval/ 2024-12-29T16:54:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lebrikizumab-f-hoffmann-la-roche-perennial-allergic-rhinitis-likelihood-of-approval/ 2024-12-29T16:54:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/belimumab-gsk-graves-diseases-likelihood-of-approval/ 2024-12-29T16:54:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lebrikizumab-f-hoffmann-la-roche-rhinosinusitis-likelihood-of-approval/ 2024-12-29T16:54:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lebrikizumab-f-hoffmann-la-roche-nasal-polyps-nasal-polyposis-likelihood-of-approval/ 2024-12-29T16:54:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/obinutuzumab-f-hoffmann-la-roche-mantle-cell-lymphoma-likelihood-of-approval/ 2024-09-09T07:08:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/obinutuzumab-f-hoffmann-la-roche-waldenstrom-macroglobulinemia-lymphoplasmacytic-lymphoma-likelihood-of-approval/ 2024-09-09T07:08:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/niraparib-gsk-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-12-29T16:54:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/avutometinib-potassium-verastem-metastatic-pancreatic-cancer-likelihood-of-approval/ 2024-12-29T16:54:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/niraparib-gsk-recurrent-malignant-glioma-likelihood-of-approval/ 2024-12-29T16:54:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azd-2373-astrazeneca-chronic-kidney-disease-chronic-renal-failure-likelihood-of-approval/ 2024-07-04T16:46:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/codrituzumab-f-hoffmann-la-roche-solid-tumor-likelihood-of-approval/ 2024-07-04T16:46:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ipilimumab-bristol-myers-squibb-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2024-12-29T16:53:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/olokizumab-r-pharm-sarcoidosis-likelihood-of-approval/ 2024-12-29T16:53:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/olokizumab-r-pharm-interstitial-lung-diseases-diffuse-parenchymal-lung-disease-likelihood-of-approval/ 2024-12-29T16:53:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/olokizumab-r-pharm-idiopathic-interstitial-pneumonia-iip-likelihood-of-approval/ 2024-12-29T16:53:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lenvatinib-mesylate-eisai-ovarian-cancer-likelihood-of-approval/ 2024-12-29T16:53:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lenvatinib-mesylate-eisai-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2024-12-29T16:53:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lenvatinib-mesylate-eisai-salivary-gland-cancer-likelihood-of-approval/ 2024-12-29T16:53:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/navidea-drops-rheumatoid-arthritis-programme-after-failed-phase-iii-trial/ 2024-07-04T15:52:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/viatris-closes-3-37bn-divestitures-with-otc-deal/ 2024-07-04T15:30:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/ean-2024-safinamide-rasagiline-pd/ 2024-07-04T15:26:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/does-h5n1-avian-influenza-have-pandemic-potential/ 2024-07-05T09:45:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/pentixapham-acquires-antibody-discovery-business-of-glycotope/ 2024-07-08T21:34:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/semnur-pharmaceuticals-to-go-public-in-2bn-spac-deal/ 2024-07-04T13:39:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/curevac-restructuring-mrna-projects/ 2024-07-04T10:29:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/lotte-biologics-plant-incheon/ 2024-07-04T10:16:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/fda-eli-lilly-kisunla-donanemab-ad/ 2024-07-04T09:50:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/boehringer-ose-cancer-immunotherapy/ 2024-07-04T08:18:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/merck-mrna-vaccine-afrigen/ 2024-07-04T08:12:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/beacon-secures-170m-to-advance-ophthalmic-gene-therapies/ 2024-12-18T16:18:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/biogen-completes-1-15bn-hi-bio-acquisition-to-expand-immunology-presence/ 2024-07-03T15:02:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/emergent-scores-us-medical-countermeasure-contracts-worth-over-250m/ 2024-07-03T14:05:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ema-approves-sanofi-dupixent/ 2024-07-03T10:13:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/gsk-curevac-vaccine-deal/ 2024-07-03T10:08:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/protecting-your-drug-products-strategies-for-preventing-metal-contamination-in-powders/ 2024-07-03T10:02:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/johnson-johnson-tb-approvals/ 2024-07-03T09:03:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/moderna-influenza-vaccine-funding/ 2024-07-03T08:38:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/left-in-limbo-when-pharma-halts-rare-disease-research/ 2024-07-26T14:01:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/eli-lillys-donanemab-wins-fda-approval-for-alzheimers-disease/ 2024-07-02T21:06:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ftc-investigates-teva-over-contested-product-patents/ 2024-07-02T17:30:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/aerovate-slashes-workforce-after-failed-phase-iib-trial/ 2024-07-02T16:52:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/eli-lilly-continues-radiopharma-push-with-140m-radionetics-partnership/ 2024-07-02T16:22:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/ean-2024-anti-cgrp-bont-a-migraine/ 2024-07-02T14:18:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/tracon-mulls-strategic-options-after-sarcoma-drug-fails-phase-ii-trial/ 2024-07-02T13:04:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-neurocrine-crinecerfont-ndas/ 2024-07-02T10:12:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/eisai-adc-development-deal/ 2024-07-02T10:03:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/the-pathway-to-preventative-health-how-pharma-can-support-the-nhs-long-term-plan/ 2024-10-14T14:40:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/samsung-bioepis-pyzchiva-fda/ 2024-07-02T08:09:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ema-astrazeneca-sipavibart-covid/ 2024-07-02T07:55:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/flt-201-spur-therapeutics-net-present-value/ 2024-07-02T02:05:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pf-07264660-pfizer-net-present-value/ 2024-12-13T02:54:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/influenza-quadrivalent-vaccine-pfizer-net-present-value/ 2024-07-02T01:46:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ctx-112-crispr-therapeutics-net-present-value/ 2024-07-02T01:46:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/suzetrigine-vertex-pharmaceuticals-net-present-value/ 2024-12-13T02:54:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rl-007-atai-life-sciences-net-present-value/ 2024-07-02T01:46:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rezatapopt-pmv-pharmaceuticals-net-present-value/ 2024-12-13T02:54:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atirmociclib-pfizer-net-present-value/ 2024-12-13T02:54:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/osivelotor-pfizer-net-present-value/ 2024-12-13T02:54:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rilvegostomig-astrazeneca-net-present-value/ 2024-07-02T01:44:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/foselutoclax-unity-biotechnology-net-present-value/ 2024-12-13T02:54:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mevrometostat-pfizer-net-present-value/ 2024-12-13T02:54:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brenetafusp-immunocore-net-present-value/ 2024-07-02T01:43:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azetukalner-xenon-pharmaceuticals-net-present-value/ 2024-07-02T01:43:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cosibelimab-checkpoint-therapeutics-net-present-value/ 2024-12-13T02:54:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sapablursen-sodium-ionis-pharmaceuticals-net-present-value/ 2024-07-02T01:42:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/asundexian-bayer-net-present-value/ 2024-07-02T01:43:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/orion-to-hand-over-exclusive-rights-to-msd-for-prostate-cancer-therapy/ 2024-07-01T16:09:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/dianthus-reveals-preclinical-data-for-its-phase-ii-neuromuscular-candidate/ 2024-07-01T15:41:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-shuns-rockets-immune-disorder-gene-therapy-over-manufacturing-shortcomings/ 2024-12-18T13:52:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/jj-looks-to-challenge-argenxs-vyvgart-with-positive-phase-iii-data/ 2024-07-01T13:48:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/pharma-sector-votes-for-post-brexit-clarity-under-new-government/ 2024-07-01T21:31:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/taurx-mhra-approval-alzheimers/ 2024-07-01T10:36:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/valneva-chikungunya-vaccine-europe/ 2024-07-01T10:29:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/uk-antibiotic-subscription-funding-model-a-route-to-market-sustainability/ 2024-07-01T09:53:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ema-chmp-roche-pnh/ 2024-07-01T08:17:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-approves-shorla-tepylute/ 2024-07-01T08:11:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/us-justice-dept-cracks-down-on-healthcare-fraud-schemes-linked-to-2-75bn-loss/ 2024-06-28T15:51:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/supreme-court-votes-against-purdue-pharmas-opioid-settlement/ 2024-06-28T15:47:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/amylyx-metabolic-diseases-market-deal/ 2024-06-28T14:30:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/coherus-offloads-humira-biosimilar-yusimry-for-40m/ 2024-06-28T14:24:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/embracing-digital-solutions-for-enhanced-patient-care/ 2024-10-14T14:21:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/from-data-to-action-igniting-the-healthcare-revolution/ 2024-10-14T14:39:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/alumis-raises-250m-in-ipo-as-biotech-stock-stirs/ 2024-06-28T13:45:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/holoclara-financing-worm-derived-therapies/ 2024-06-28T10:12:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/eisai-biogen-launch-leqembi/ 2024-06-28T10:09:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/chmp-pfizer-biontech-vaccine/ 2024-06-28T08:24:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/abbvie-acquires-celsius-therapeutics/ 2024-06-28T08:09:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ai-and-stable-funding-environments-are-catalysts-for-biotech-assets/ 2024-06-27T18:43:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/2seventy-bio-completes-40m-haemophilia-a-program-deal-with-novo-nordisk/ 2024-06-27T16:26:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/verona-scores-fda-approval-for-ohtuvayre-as-copd-maintenance-therapy/ 2024-06-27T18:52:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/biotech-fund-curie-bio-augments-reserves-with-380m-to-boost-startups/ 2024-06-27T13:55:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/fda-verona-ohtuvayre-us-copd-exacerbator-market/ 2024-06-27T12:31:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/formation-bio-secures-372m-funds/ 2024-06-27T10:22:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/us-cdc-rsv-vaccination/ 2024-06-27T10:18:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/novo-nordisk-ocedurenone-flop-816m/ 2024-06-27T09:04:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-daiichi-sankyo-msd-crl/ 2024-06-27T08:32:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/abbvie-fda-approval-epkinly/ 2024-06-27T08:23:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/capturing-the-genai-boom-for-drug-development/ 2024-07-22T16:00:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/glp-1-shortages-are-not-expected-to-resolve-this-year-says-ema-director/ 2024-06-27T07:29:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/lilly-joins-fellow-pharma-giants-in-openai-partnership/ 2024-06-26T19:08:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/sharp-services-announces-expansion-in-pennsylvania-to-facilitate-growth-in-sterile-injectable-market/ 2024-06-27T08:22:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/harnessing-the-power-of-ecoa-in-clinical-trials/ 2024-06-26T16:28:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/impact-implications-monthly-price-cap-asthma-inhalers/ 2024-06-26T13:38:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/carisma-fda-fast-track-status/ 2024-12-18T13:48:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/china-mcrc-treatment-simcere/ 2024-06-26T10:46:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-abbvie-parkinsons-therapy/ 2024-06-26T09:01:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/astrazeneca-tagrisso-japan-lung-cancer/ 2024-06-26T08:54:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/pharma-ma-the-top-high-value-deals-in-2023/ 2024-06-25T20:19:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/magazine-uks-new-netflix-style-funding-model-for-antibiotics-goes-live/ 2024-06-25T19:42:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/buyers-guide/medical-packaging/ 2024-07-15T10:30:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/buyers-guide/pharma-packaging/ 2025-11-05T11:38:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ethris-shares-positive-data-with-mrna-drug-following-new-funding/ 2024-06-25T15:54:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/merck-kgaa-abandons-phase-iii-trial-for-1-08bn-head-neck-cancer-drug-2/ 2024-06-25T13:37:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/oncoinvent-radspherin-ovarian-cancer/ 2024-06-25T10:19:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/novavax-ema-covid-vaccine/ 2024-06-25T10:14:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/gsk-omjjara-japan-myelofibrosis/ 2024-06-25T08:28:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/novo-nordisk-facility-clayton/ 2024-06-28T10:30:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/uks-clinical-landscape-faces-new-reality-as-international-competition-heats-up/ 2024-06-24T20:20:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/buyers-guide/pharmaceutical-consulting/ 2025-11-05T11:39:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/alnylam-reveals-positive-phase-iii-results-for-rare-heart-disease-drug-vutrisiran/ 2024-06-24T15:59:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/osteoporosis-market-17-9bn-7mm-2033/ 2024-06-24T15:54:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ada-2024-altimmunes-glp-1-drug-shows-weight-loss-potential/ 2024-06-24T15:49:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/bms-expands-krazatis-fda-label-to-include-colorectal-cancer/ 2024-06-24T15:23:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/fda-awarded-mrna-vaccines-2023/ 2024-06-24T15:21:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/blockbuster-deals-cmos-ma/ 2024-06-24T15:06:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/alimera-sciences-shares-jump-by-77-after-being-acquired-by-ani/ 2024-06-24T15:04:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/navigating-the-global-epilepsy-clinical-trial-landscape-in-2024/ 2024-06-24T16:38:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/podcast-4-doing-digital-deals-in-life-sciences-due-diligence/ 2025-03-28T16:23:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/daiichi-sankyo-therapy-approval-japan/ 2024-06-24T10:42:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-argenx-vyvgart-hytrulo/ 2024-06-24T10:36:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/the-evolution-of-contract-packagers-delivering-sustainability-for-injectables-packaging/ 2025-07-03T10:37:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/melodia-alivexis-agreement-mdi-0151/ 2024-06-24T08:19:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ec-approves-takeda-fruzaqla/ 2024-06-24T08:12:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/eha-2024-monoclonal-antibodies-continue-to-dominate-multiple-myeloma-treatments/ 2024-07-02T21:01:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/sareptas-elevidys-secures-us-label-expansion-for-dmd/ 2024-06-21T16:15:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/tectonic-bets-on-gpcr-heart-failure-drug-following-reverse-merger-with-avrobio/ 2024-06-21T14:15:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/who-warns-of-harmful-fake-ozempic-in-circulation-in-americas-and-europe/ 2024-06-21T13:39:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/south-korea-seeks-accelerate-drug-reimbursement-administration-process/ 2024-06-26T08:16:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/emergent-sterile-bora/ 2024-10-02T15:15:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/johnson-fda-tremfya-crohns/ 2024-06-21T10:38:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/sanofi-biovac-polio-vaccines-africa/ 2024-06-21T07:40:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/astrazenecas-truqap-faslodex-approval/ 2024-06-21T07:33:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/will-whos-new-guidance-spur-hepatitis-b-immunisation/ 2024-06-18T21:00:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ionctura-raises-nearly-86m-in-series-b-to-fund-phase-ii-cancer-trials/ 2024-06-20T15:56:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/mhra-disallows-epilepsy-drug-topiramate-use-for-pregnant-patients/ 2024-06-20T15:55:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/basilea-sells-rights-to-microtubule-drug-to-glioblastoma-foundation/ 2024-06-20T15:25:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/how-improving-econsent-can-enhance-patient-retention-for-clinical-trials/ 2024-08-02T14:14:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/university-of-birmingham-drug-development/ 2024-06-20T10:24:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/botanix-hyperhidrosis-sofdra-fda/ 2024-06-20T10:16:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/gc-cell-pt-bifarma-t-cell-therapy-indonesia/ 2024-12-18T11:13:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/china-nmpa-dizal-golidocitinib/ 2024-06-20T07:53:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ilution-travoprost-glaukos-ocular-hypertension-likelihood-of-approval/ 2024-12-29T16:47:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ilution-travoprost-glaukos-open-angle-glaucoma-likelihood-of-approval/ 2024-12-29T16:47:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ima-203cd8-immatics-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2025-01-23T02:27:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ibi-343-innovent-biologics-solid-tumor-likelihood-of-approval/ 2024-12-29T16:50:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tyra-200-tyra-biosciences-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2024-06-19T17:42:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/denosumab-biosimilar-celltrion-osteoporosis-likelihood-of-approval/ 2025-01-23T02:14:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kt-333-kymera-therapeutics-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2025-01-23T02:17:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgc-0228-brightgene-bio-medical-technology-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-23T02:12:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mrg-004a-shanghai-miracogen-cervical-cancer-likelihood-of-approval/ 2024-06-19T17:39:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bi-905711-boehringer-ingelheim-international-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2024-07-06T05:16:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zimberelimab-arcus-biosciences-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-22T18:07:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zimberelimab-arcus-biosciences-squamous-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-22T18:07:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ecubectedin-pharma-mar-small-cell-lung-cancer-likelihood-of-approval/ 2024-06-19T17:38:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zectivimod-lg-chem-ulcerative-colitis-likelihood-of-approval/ 2025-01-22T18:04:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cb-307-crescendo-biologics-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2024-06-19T17:38:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/blb-01d1-bristol-myers-squibb-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-22T18:06:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/disitamab-vedotin-pfizer-metastatic-colorectal-cancer-likelihood-of-approval/ 2025-01-22T17:59:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/disitamab-vedotin-pfizer-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2025-01-22T18:00:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/disitamab-vedotin-pfizer-human-epidermal-growth-factor-receptor-2-positive-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2025-01-22T18:00:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/disitamab-vedotin-pfizer-esophageal-cancer-likelihood-of-approval/ 2025-01-22T17:59:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mosunetuzumab-genentech-usa-refractory-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2025-01-22T17:54:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ima-203-immatics-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2024-07-06T05:01:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sea-cd40-pfizer-metastatic-melanoma-likelihood-of-approval/ 2024-06-20T09:28:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sea-cd40-pfizer-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-06-19T17:34:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gene-therapy-to-activate-4-1bbl-and-to-target-cd19-for-b-cell-malignancies-bristol-myers-squibb-non-hodgkin-lymphoma-likelihood-of-approval/ 2024-09-09T06:48:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bi-836858-boehringer-ingelheim-international-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-22T02:09:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rituximab-biosimilar-shanghai-henlius-biotech-follicular-lymphoma-likelihood-of-approval/ 2025-01-22T17:37:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/odevixibat-ipsen-biliary-atresia-likelihood-of-approval/ 2024-06-19T17:33:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bi-836858-boehringer-ingelheim-international-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-likelihood-of-approval/ 2025-01-22T02:09:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bi-836858-boehringer-ingelheim-international-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-22T02:09:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ifebemtinib-inxmed-nanjing-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-22T16:41:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trabectedin-pharma-mar-chondrosarcoma-likelihood-of-approval/ 2025-01-22T16:39:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/birch-triterpenes-chiesi-farmaceutici-radiodermatitis-likelihood-of-approval/ 2024-06-19T17:31:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tucatinib-pfizer-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval/ 2025-01-22T16:34:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trabectedin-pharma-mar-osteosarcoma-likelihood-of-approval/ 2025-01-22T16:39:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tucatinib-pfizer-gastric-cancer-likelihood-of-approval/ 2025-01-22T16:33:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tucatinib-pfizer-bladder-cancer-likelihood-of-approval/ 2025-01-22T16:33:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tucatinib-pfizer-transitional-cell-cancer-urothelial-cell-cancer-likelihood-of-approval/ 2025-01-22T16:34:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brentuximab-vedotin-pfizer-follicular-lymphoma-likelihood-of-approval/ 2025-01-22T02:22:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tucatinib-pfizer-cervical-cancer-likelihood-of-approval/ 2025-01-22T16:33:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/obinutuzumab-f-hoffmann-la-roche-refractory-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2024-09-09T06:18:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brentuximab-vedotin-pfizer-systemic-sclerosis-scleroderma-likelihood-of-approval/ 2025-01-22T02:21:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brentuximab-vedotin-pfizer-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-22T02:21:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nitronazine-guangzhou-magpie-pharmaceutical-amyotrophic-lateral-sclerosis-likelihood-of-approval/ 2024-06-19T16:11:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abelacimab-anthos-therapeutics-venous-vein-thrombosis-likelihood-of-approval/ 2025-01-21T17:02:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rns-60-revalesio-acute-ischemic-stroke-likelihood-of-approval/ 2024-06-19T16:10:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ceb-01-cebiotex-leiomyosarcoma-likelihood-of-approval/ 2025-01-21T17:00:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ceb-01-cebiotex-pleomorphic-liposarcoma-likelihood-of-approval/ 2025-01-21T17:00:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ceb-01-cebiotex-soft-tissue-sarcoma-likelihood-of-approval/ 2025-01-21T17:00:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ceb-01-cebiotex-nerve-sheath-tumor-likelihood-of-approval/ 2025-01-21T17:00:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/elraglusib-actuate-therapeutics-post-essential-thrombocythemia-myelofibrosis-post-et-mf-likelihood-of-approval/ 2025-01-21T16:59:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ulixertinib-biomed-valley-discoveries-neurofibromatoses-type-i-von-recklinghausen-s-disease-likelihood-of-approval/ 2024-06-19T16:07:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adakitug-bristol-myers-squibb-hormone-sensitive-prostate-cancer-likelihood-of-approval/ 2025-01-21T16:57:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azd-1705-astrazeneca-dyslipidemia-likelihood-of-approval/ 2025-01-21T16:56:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bms-986465-bristol-myers-squibb-neuroinflammation-likelihood-of-approval/ 2024-06-19T16:04:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sabestomig-astrazeneca-crohn-s-disease-regional-enteritis-likelihood-of-approval/ 2025-01-21T16:53:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ihat-02-nemysis-iron-deficiency-anemia-likelihood-of-approval/ 2024-06-19T16:03:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/a-2b694-a2-biotherapeutics-metastatic-ovarian-cancer-likelihood-of-approval/ 2024-07-05T18:21:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/a-2b694-a2-biotherapeutics-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-07-05T18:21:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/a-2b694-a2-biotherapeutics-malignant-mesothelioma-likelihood-of-approval/ 2024-07-05T18:21:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/a-2b694-a2-biotherapeutics-metastatic-colorectal-cancer-likelihood-of-approval/ 2024-07-05T18:21:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ht-6184-halia-therapeutics-acute-inflammation-likelihood-of-approval/ 2025-01-21T16:53:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/a-2b694-a2-biotherapeutics-metastatic-pancreatic-cancer-likelihood-of-approval/ 2024-07-05T18:21:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nitric-oxide-sanotize-research-and-development-rhinosinusitis-likelihood-of-approval/ 2025-01-21T16:53:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bidridistrogene-xeboparvovec-sarepta-therapeutics-limb-girdle-muscular-dystrophy-likelihood-of-approval/ 2025-01-21T16:51:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/day-one-targets-the-growing-adc-market-with-mabcare-acquisition/ 2024-06-19T15:55:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/sobi-scores-eu-approval-for-haemophilia-a-replacement-therapy-altuvoct/ 2024-06-19T14:43:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/pharma-and-medtech-companies-need-to-team-up-for-wound-management/ 2024-06-19T10:23:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/unither-monroe-county-facility-modernisation/ 2024-06-19T10:18:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/marea-launches-cardiometabolic-therapies/ 2024-06-19T10:10:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ascidian-roche-rna-therapies/ 2024-06-19T08:15:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/abbvie-skyrizi-fda-approval/ 2024-06-19T08:06:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atezolizumab-tiragolumab-f-hoffmann-la-roche-solid-tumor-likelihood-of-approval/ 2024-12-29T16:53:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/crte-7a2-beijing-corregene-biotechnology-anal-cancer-likelihood-of-approval/ 2024-06-19T05:01:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/crte-7a2-beijing-corregene-biotechnology-head-and-neck-cancer-likelihood-of-approval/ 2024-06-19T05:01:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/crte-7a2-beijing-corregene-biotechnology-cervical-cancer-likelihood-of-approval/ 2024-06-19T05:01:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bst-2123-bostal-drug-delivery-co-diabetes-likelihood-of-approval/ 2024-06-19T05:00:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/car-t-cell-therapy-shanghai-unicar-therapy-bio-medicine-technology-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2024-06-19T05:00:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/influenza-strain-a-h5n1-vaccine-1-gsk-pandemic-influenza-likelihood-of-approval/ 2024-12-29T16:53:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/influenza-strain-a-h5n1-vaccine-1-gsk-influenza-a-virus-h5n1-subtype-infections-likelihood-of-approval/ 2024-12-29T16:53:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xc-8-jsc-valenta-pharmaceuticals-dry-cough-likelihood-of-approval/ 2024-06-19T04:59:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xc-8-jsc-valenta-pharmaceuticals-acute-upper-respiratory-tract-infections-likelihood-of-approval/ 2024-06-19T04:59:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xc-8-jsc-valenta-pharmaceuticals-viral-respiratory-tract-infection-likelihood-of-approval/ 2024-06-19T04:58:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xc-8-jsc-valenta-pharmaceuticals-acute-bronchitis-likelihood-of-approval/ 2024-06-19T04:58:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azd-0233-astrazeneca-dilated-cardiomyopathy-likelihood-of-approval/ 2024-12-29T16:53:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anti-fibrotic-agent-boehringer-ingelheim-international-myocardial-fibrosis-likelihood-of-approval/ 2024-06-19T04:57:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anti-fibrotic-agent-boehringer-ingelheim-international-kidney-fibrosis-likelihood-of-approval/ 2024-06-19T04:57:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/afyx-007-afyx-therapeutics-head-and-neck-cancer-likelihood-of-approval/ 2024-06-19T04:57:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lpcn-2401-lipocine-obesity-likelihood-of-approval/ 2024-06-19T04:57:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/semaglutide-chia-tai-tianqing-pharmaceutical-group-type-2-diabetes-likelihood-of-approval/ 2024-06-19T04:56:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/m2r-001-xcell-medical-solutions-muscle-injury-likelihood-of-approval/ 2024-06-19T04:56:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/prn-00201-proniras-opium-opioid-addiction-likelihood-of-approval/ 2024-06-19T04:55:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/asp-4396-astellas-pharma-solid-tumor-likelihood-of-approval/ 2024-12-29T16:53:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mei-004-nanjing-minova-pharmaceutical-technology-alopecia-likelihood-of-approval/ 2024-07-06T05:26:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/iloprost-phait-lung-cancer-likelihood-of-approval/ 2024-06-19T04:55:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cb-0135-cosmo-pharmaceuticals-limited-distal-colitis-likelihood-of-approval/ 2024-06-19T04:54:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cb-0135-cosmo-pharmaceuticals-proctitis-likelihood-of-approval/ 2024-06-19T04:54:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pembrolizumab-biosimilar-amgen-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-29T16:53:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ranibizumab-biosimilar-incepta-pharmaceuticals-diabetic-macular-edema-likelihood-of-approval/ 2024-06-19T04:53:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fit-003-guangzhou-fineimmune-biotechnology-solid-tumor-likelihood-of-approval/ 2024-06-19T04:53:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/latrepirdine-dihydrochloride-bigespas-dementia-associated-with-alzheimer-s-disease-likelihood-of-approval/ 2024-06-19T04:53:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/a-005-alumis-encephalomyelitis-likelihood-of-approval/ 2024-06-19T04:52:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/a-005-alumis-neurodegenerative-diseases-likelihood-of-approval/ 2024-06-19T04:52:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/a-005-alumis-parkinson-s-disease-likelihood-of-approval/ 2024-06-19T04:52:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/a-005-alumis-multiple-sclerosis-likelihood-of-approval/ 2024-06-19T04:52:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nnc-06500013-novo-nordisk-type-2-diabetes-likelihood-of-approval/ 2024-06-19T04:51:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pf-07820435-pfizer-transitional-cell-carcinoma-urothelial-cell-carcinoma-likelihood-of-approval/ 2024-12-29T16:53:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pf-07820435-pfizer-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-29T16:53:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/na-941-biomed-industries-metabolic-dysfunction-associated-steatohepatitis-mash-likelihood-of-approval/ 2024-12-29T16:53:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/undisclosed-program-viiv-healthcare-human-immunodeficiency-virus-hiv-infections-aids-likelihood-of-approval/ 2024-06-19T04:50:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cx-001-calissa-therapeutics-nevus-likelihood-of-approval/ 2024-06-19T04:50:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cx-001-calissa-therapeutics-rosacea-likelihood-of-approval/ 2024-06-19T04:50:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/celecoxib-tucidinostat-great-novel-therapeutics-biotech-medicals-metastatic-colorectal-cancer-likelihood-of-approval/ 2024-12-29T16:53:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vardenafil-ltr-pharma-erectile-dysfunction-likelihood-of-approval/ 2024-06-19T04:49:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azd-0292-astrazeneca-bronchiectasis-likelihood-of-approval/ 2024-07-06T05:26:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cannabidiol-3-sapient-therapeutics-epilepsy-likelihood-of-approval/ 2024-06-19T04:48:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sis-302aa-sisaf-alopecia-areata-likelihood-of-approval/ 2024-07-06T05:26:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cmet-axl-selective-inhibitor-bioseedin-gastric-cancer-likelihood-of-approval/ 2024-06-19T04:47:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fxia-inhibitor-bioseedin-arterial-thrombosis-likelihood-of-approval/ 2024-06-19T04:47:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fxia-inhibitor-bioseedin-deep-vein-thrombosis-dvt-likelihood-of-approval/ 2024-06-19T04:47:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cs1-plus-bcma-car-t-bioseedin-multiple-myeloma-kahler-disease-likelihood-of-approval/ 2024-06-19T04:45:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pembrolizumab-biosimilar-samsung-bioepis-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-06-19T04:45:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sul-238-gen-ilac-ve-saglik-urunleri-alzheimer-s-disease-likelihood-of-approval/ 2024-06-19T04:44:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/qy-1-t-zhongke-qiyuan-shenzhen-biotechnology-hepatocellular-carcinoma-likelihood-of-approval/ 2024-06-19T04:43:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ink-acute-myeloid-leukemia-nuwacell-biotechnology-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-likelihood-of-approval/ 2024-06-19T04:43:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jnj-79032421-johnson-johnson-malignant-pleural-mesothelioma-likelihood-of-approval/ 2024-06-19T04:43:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/evolocumab-biosimilar-cinnagen-hyperlipidemia-likelihood-of-approval/ 2024-06-19T04:42:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nn-9542-novo-nordisk-diabetes-likelihood-of-approval/ 2024-12-29T16:53:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tsn-1611-tyligand-biotechnology-shanghai-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-06-19T04:42:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tsn-1611-tyligand-biotechnology-shanghai-solid-tumor-likelihood-of-approval/ 2024-06-19T04:41:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tsn-1611-tyligand-biotechnology-shanghai-pancreatic-cancer-likelihood-of-approval/ 2024-06-19T04:41:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tsn-1611-tyligand-biotechnology-shanghai-colorectal-cancer-likelihood-of-approval/ 2024-06-19T04:41:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ptt-936-pyrotech-therapeutics-solid-tumor-likelihood-of-approval/ 2024-06-19T17:12:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/respiratory-syncytial-virus-vaccine-2-sanofi-respiratory-syncytial-virus-rsv-infections-likelihood-of-approval/ 2024-07-06T05:26:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dalfampridine-er-solaxa-episodic-ataxia-type-2-likelihood-of-approval/ 2024-06-19T04:40:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nn-9441-inversago-pharma-obesity-likelihood-of-approval/ 2024-06-19T04:39:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rg-6436-genentech-usa-pseudomonas-aeruginosa-infections-likelihood-of-approval/ 2024-06-19T04:39:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rg-6436-genentech-usa-enterobacteriaceae-infections-likelihood-of-approval/ 2024-06-19T04:39:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rg-6436-genentech-usa-acinetobacter-infections-likelihood-of-approval/ 2024-06-19T04:38:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rg-6436-genentech-usa-urinary-tract-infections-likelihood-of-approval/ 2024-06-19T04:38:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ibi-3002-innovent-biologics-asthma-likelihood-of-approval/ 2024-06-19T04:38:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adx-850-adarx-pharmaceuticals-hypertension-likelihood-of-approval/ 2024-06-19T04:37:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vx-407-vertex-pharmaceuticals-polycystic-kidney-disease-likelihood-of-approval/ 2024-12-29T16:53:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/arv-393-arvinas-angioimmunoblastic-t-cell-lymphoma-aitl-immunoblastic-lymphadenopathy-likelihood-of-approval/ 2024-12-29T16:53:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/arv-393-arvinas-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2024-12-29T16:53:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ns-136-neushen-therapeutics-schizophrenia-likelihood-of-approval/ 2024-12-29T16:53:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/incb-161734-incyte-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-29T16:52:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/opl-025b-overseas-pharmaceuticals-diabetes-likelihood-of-approval/ 2024-06-19T04:35:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/opl-022-overseas-pharmaceuticals-hypertension-likelihood-of-approval/ 2024-06-19T04:35:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nbi-1076986-neurocrine-biosciences-movement-disorders-likelihood-of-approval/ 2024-12-29T16:52:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xm-001-hefei-starry-gene-biotechnology-wet-neovascular-exudative-macular-degeneration-likelihood-of-approval/ 2024-07-06T05:26:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ilution-travoprost-glaukos-open-angle-glaucoma-likelihood-of-approval-2/ 2024-12-29T16:52:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ilution-travoprost-glaukos-ocular-hypertension-likelihood-of-approval-2/ 2024-12-29T16:52:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dapagliflozin-glimepiride-jin-yang-pharmaceutical-type-2-diabetes-likelihood-of-approval/ 2024-06-19T04:33:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azd-9829-astrazeneca-hematological-tumor-likelihood-of-approval/ 2024-06-19T04:33:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/etx-197-ensem-therapeutics-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2024-12-29T16:52:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/etx-197-ensem-therapeutics-peritoneal-cancer-likelihood-of-approval/ 2024-12-29T16:52:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/etx-197-ensem-therapeutics-metastatic-ovarian-cancer-likelihood-of-approval/ 2024-12-29T16:52:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/etx-197-ensem-therapeutics-fallopian-tube-cancer-likelihood-of-approval/ 2024-12-29T16:52:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/etx-197-ensem-therapeutics-solid-tumor-likelihood-of-approval/ 2024-12-29T16:52:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/etx-197-ensem-therapeutics-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-29T16:52:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/amg-355-amgen-metastatic-colorectal-cancer-likelihood-of-approval/ 2024-12-29T16:52:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/amg-355-amgen-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-29T16:52:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/amg-355-amgen-solid-tumor-likelihood-of-approval/ 2024-12-29T16:52:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/amg-355-amgen-gastric-cancer-likelihood-of-approval/ 2024-12-29T16:52:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jv-clinical-programs-shionogi-apnimed-sleep-science-obstructive-sleep-apnea-likelihood-of-approval/ 2024-12-29T16:52:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rem-422-remix-therapeutics-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2024-06-19T04:29:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rem-422-remix-therapeutics-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2024-06-19T04:28:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rem-422-remix-therapeutics-myelodysplastic-syndrome-likelihood-of-approval/ 2024-06-19T04:28:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pf-08046044-pfizer-peripheral-t-cell-lymphomas-ptcl-likelihood-of-approval/ 2024-06-19T04:28:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pf-08046044-pfizer-anaplastic-large-cell-lymphoma-alcl-likelihood-of-approval/ 2024-06-19T04:27:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pf-08046044-pfizer-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2024-06-19T04:27:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pf-08046044-pfizer-hodgkin-lymphoma-b-cell-hodgkin-lymphoma-likelihood-of-approval/ 2024-06-19T04:27:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pf-08046044-pfizer-lymphoma-likelihood-of-approval/ 2024-06-19T04:27:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/incb-100658-incyte-myelofibrosis-likelihood-of-approval/ 2024-12-29T16:52:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/incb-100658-incyte-essential-thrombocythemia-likelihood-of-approval/ 2024-12-29T16:52:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/incb-100658-incyte-polycythemia-vera-likelihood-of-approval/ 2024-12-29T16:52:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anti-her2-car-t-cells-shanghai-first-song-therapeutics-metastatic-colorectal-cancer-likelihood-of-approval/ 2024-07-06T05:25:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anti-her2-car-t-cells-shanghai-first-song-therapeutics-solid-tumor-likelihood-of-approval/ 2024-07-06T05:25:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anti-her2-car-t-cells-shanghai-first-song-therapeutics-metastatic-pancreatic-cancer-likelihood-of-approval/ 2024-07-06T05:25:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anti-her2-car-t-cells-shanghai-first-song-therapeutics-metastatic-breast-cancer-likelihood-of-approval/ 2024-07-06T05:25:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anti-her2-car-t-cells-shanghai-first-song-therapeutics-gastric-cancer-likelihood-of-approval/ 2024-07-06T05:25:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kk-2269-kyowa-kirin-solid-tumor-likelihood-of-approval/ 2024-06-19T04:24:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nn-4002-novo-nordisk-solid-tumor-likelihood-of-approval/ 2024-12-29T16:52:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nn-4002-novo-nordisk-non-hodgkin-lymphoma-likelihood-of-approval/ 2024-12-29T16:52:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jwk-006-chengdu-genevector-biotechnology-juvenile-macular-degeneration-stargardt-disease-likelihood-of-approval/ 2024-06-19T04:23:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bms-986454-bristol-myers-squibb-autoimmune-disorders-likelihood-of-approval/ 2024-09-09T07:07:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gs1-144-changchun-jinsai-pharmaceutical-vasomotor-symptoms-non-menopausal-likelihood-of-approval/ 2024-12-29T16:52:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anti-cea-car-t-cells-shanghai-first-song-therapeutics-metastatic-adenocarcinoma-of-the-pancreas-likelihood-of-approval/ 2024-07-06T05:25:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anti-cea-car-t-cells-shanghai-first-song-therapeutics-metastatic-colorectal-cancer-likelihood-of-approval/ 2024-07-06T05:25:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anti-cea-car-t-cells-shanghai-first-song-therapeutics-small-intestine-cancer-likelihood-of-approval/ 2024-07-06T05:25:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anti-cea-car-t-cells-shanghai-first-song-therapeutics-esophageal-cancer-likelihood-of-approval/ 2024-07-06T05:25:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anti-cea-car-t-cells-shanghai-first-song-therapeutics-solid-tumor-likelihood-of-approval/ 2024-07-06T05:25:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anti-cea-car-t-cells-shanghai-first-song-therapeutics-gastric-cancer-likelihood-of-approval/ 2024-07-06T05:25:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bcma-gprc5d-car-t-cells-guangzhou-bio-gene-technology-refractory-multiple-myeloma-likelihood-of-approval/ 2024-06-19T04:20:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bcma-gprc5d-car-t-cells-guangzhou-bio-gene-technology-relapsed-multiple-myeloma-likelihood-of-approval/ 2024-06-19T04:20:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/impt-514-immpact-bio-usa-lupus-nephritis-likelihood-of-approval/ 2024-12-29T16:52:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/impt-514-immpact-bio-usa-systemic-lupus-erythematosus-likelihood-of-approval/ 2024-12-29T16:52:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fc-12738-neurodegenerative-disease-research-amyotrophic-lateral-sclerosis-likelihood-of-approval/ 2024-06-19T04:19:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gen-3017-genmab-hodgkin-lymphoma-b-cell-hodgkin-lymphoma-likelihood-of-approval/ 2024-12-29T16:51:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rm-718-rhythm-pharmaceuticals-obesity-likelihood-of-approval/ 2024-06-19T04:19:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/npx-267-nextpoint-therapeutics-gastric-cancer-likelihood-of-approval/ 2024-12-29T16:51:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sh-201-shorla-oncology-gastrointestinal-tumor-likelihood-of-approval/ 2024-06-19T04:18:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sh-201-shorla-oncology-myelodysplastic-syndrome-likelihood-of-approval/ 2024-06-19T04:17:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sh-201-shorla-oncology-chronic-myelocytic-leukemia-cml-chronic-myeloid-leukemia-likelihood-of-approval/ 2024-06-19T04:17:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sh-201-shorla-oncology-acute-lymphocytic-leukemia-all-acute-lymphoblastic-leukemia-likelihood-of-approval/ 2024-06-19T04:17:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/wgc-043-chengdu-westgene-biopharma-epstein-barr-virus-hhv-4-infections-likelihood-of-approval/ 2024-06-19T04:17:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nicorandil-er-auxilius-pharma-chronic-stable-angina-likelihood-of-approval/ 2024-12-29T16:51:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anti-gprc5d-car-t-cell-therapy-protheragen-refractory-multiple-myeloma-likelihood-of-approval/ 2024-06-19T04:15:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anti-gprc5d-car-t-cell-therapy-protheragen-relapsed-multiple-myeloma-likelihood-of-approval/ 2024-06-19T04:15:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brb-002-bitterroot-bio-atherosclerosis-likelihood-of-approval/ 2024-06-19T04:15:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sr-604-equilibra-bioscience-hemophilia-b-factor-ix-deficiency-likelihood-of-approval/ 2024-06-19T04:14:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sr-604-equilibra-bioscience-hemophilia-a-factor-viii-deficiency-likelihood-of-approval/ 2024-06-19T04:13:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/177lu-lu-rhpsma-10-1-blue-earth-therapeutics-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2024-12-29T16:51:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/snv-1521-synnovation-therapeutics-solid-tumor-likelihood-of-approval/ 2024-06-19T04:13:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pf-07911145-biontech-herpes-zoster-shingles-likelihood-of-approval/ 2024-06-19T04:12:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pf-07941314-pfizer-respiratory-syncytial-virus-rsv-infections-likelihood-of-approval/ 2024-06-19T04:11:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atp-152-boehringer-ingelheim-international-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2024-12-29T16:51:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atp-150-boehringer-ingelheim-international-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2024-06-19T04:11:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pm-54-pharma-mar-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-29T16:51:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azd-0754-astrazeneca-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2024-06-19T04:10:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pertuzumab-biosimilar-mabscale-metastatic-breast-cancer-likelihood-of-approval/ 2024-12-29T16:51:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pertuzumab-biosimilar-mabscale-breast-cancer-likelihood-of-approval/ 2024-12-29T16:51:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/db-1312-duality-biologics-shanghai-squamous-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-29T16:51:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/db-1312-duality-biologics-shanghai-esophageal-cancer-likelihood-of-approval/ 2024-12-29T16:51:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/db-1312-duality-biologics-shanghai-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2024-12-29T16:51:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/db-1312-duality-biologics-shanghai-solid-tumor-likelihood-of-approval/ 2024-12-29T16:51:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/db-1312-duality-biologics-shanghai-ovarian-cancer-likelihood-of-approval/ 2024-12-29T16:51:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/db-1312-duality-biologics-shanghai-breast-cancer-likelihood-of-approval/ 2024-12-29T16:51:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fbta-05-lindis-biotech-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2024-09-09T07:07:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/snc-102-shanghai-simnova-biotechnology-refractory-multiple-myeloma-likelihood-of-approval/ 2024-06-19T04:06:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/snc-102-shanghai-simnova-biotechnology-relapsed-multiple-myeloma-likelihood-of-approval/ 2024-06-19T04:06:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/snc-115-shanghai-simnova-biotechnology-neuroendocrine-carcinoma-likelihood-of-approval/ 2024-06-19T04:06:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/snc-115-shanghai-simnova-biotechnology-small-cell-lung-cancer-likelihood-of-approval/ 2024-06-19T04:05:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/db-1311-biontech-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-29T16:51:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hydrocortisone-eton-pharmaceuticals-adrenal-insufficiency-likelihood-of-approval/ 2024-06-19T04:04:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sc-car4brain-brainchild-bio-pediatric-diffuse-intrinsic-pontine-glioma-likelihood-of-approval/ 2024-06-19T04:04:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sc-car4brain-brainchild-bio-central-nervous-system-cns-tumor-likelihood-of-approval/ 2024-06-19T04:04:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abbv-101-abbvie-follicular-lymphoma-likelihood-of-approval/ 2024-09-09T07:06:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bcma-car-nk-cheetah-cell-therapeutics-refractory-multiple-myeloma-likelihood-of-approval/ 2024-06-19T04:03:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bcma-car-nk-cheetah-cell-therapeutics-relapsed-multiple-myeloma-likelihood-of-approval/ 2024-06-19T04:03:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abbv-932-abbvie-generalized-anxiety-disorder-gad-likelihood-of-approval/ 2024-12-29T16:51:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ezetimibe-obicetrapib-newamsterdam-pharma-company-heterozygous-familial-hypercholesterolemia-hefh-likelihood-of-approval/ 2024-09-09T07:06:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pd-1-silent-psma-or-psca-targeted-car-t-shanghai-unicar-therapy-bio-medicine-technology-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2024-06-19T04:02:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tsc-204-hla-a-01-01-tscan-therapeutics-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-06-19T04:02:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tsc-204-hla-a-01-01-tscan-therapeutics-anal-cancer-likelihood-of-approval/ 2024-06-19T04:02:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tsc-204-hla-a-01-01-tscan-therapeutics-head-and-neck-cancer-likelihood-of-approval/ 2024-06-19T04:01:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tsc-204-hla-a-01-01-tscan-therapeutics-melanoma-likelihood-of-approval/ 2024-06-19T04:01:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tsc-204-hla-a-01-01-tscan-therapeutics-cervical-cancer-likelihood-of-approval/ 2024-06-19T04:01:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tsc-204-hla-a-01-01-tscan-therapeutics-ovarian-cancer-likelihood-of-approval/ 2024-06-19T04:00:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tsc-204-hla-c-07-02-tscan-therapeutics-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-12-29T16:51:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gsk-4406371a-gsk-rubella-german-measles-likelihood-of-approval/ 2024-12-29T16:51:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gsk-4406371a-gsk-mumps-likelihood-of-approval/ 2024-12-29T16:51:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gsk-4406371a-gsk-measles-likelihood-of-approval/ 2024-12-29T16:51:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pf-08046050-pfizer-squamous-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-07-06T05:24:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pf-08046050-pfizer-metastatic-colorectal-cancer-likelihood-of-approval/ 2024-07-06T05:24:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pf-08046050-pfizer-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2024-07-06T05:24:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/homsc-200-cytora-diabetic-foot-ulcers-likelihood-of-approval/ 2024-06-19T03:57:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/som-401-inflammasome-therapeutics-geographic-atrophy-likelihood-of-approval/ 2024-09-09T07:06:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vdphl-veradermics-androgenic-alopecia-likelihood-of-approval/ 2024-12-29T16:51:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/acetaminophen-naltrexone-allodynic-therapeutics-migraine-likelihood-of-approval/ 2024-12-29T16:50:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bay-3546828-bayer-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2024-06-19T03:55:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bay-3018250-bayer-deep-vein-thrombosis-dvt-likelihood-of-approval/ 2024-12-29T16:50:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sc-262-sana-biotechnology-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2024-12-29T16:50:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sc-262-sana-biotechnology-primary-mediastinal-b-cell-lymphoma-likelihood-of-approval/ 2024-12-29T16:50:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sc-262-sana-biotechnology-follicular-lymphoma-likelihood-of-approval/ 2024-12-29T16:50:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sc-262-sana-biotechnology-mantle-cell-lymphoma-likelihood-of-approval/ 2024-12-29T16:50:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sc-262-sana-biotechnology-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2024-12-29T16:50:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/arts-021-avenzo-therapeutics-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-06-19T03:53:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/arts-021-avenzo-therapeutics-metastatic-transitional-urothelial-tract-cancer-likelihood-of-approval/ 2024-06-19T03:52:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/arts-021-avenzo-therapeutics-gastroesophageal-ge-junction-carcinomas-likelihood-of-approval/ 2024-06-19T03:52:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/arts-021-avenzo-therapeutics-endometrial-cancer-likelihood-of-approval/ 2024-06-19T03:51:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/arts-021-avenzo-therapeutics-small-cell-lung-cancer-likelihood-of-approval/ 2024-06-19T03:51:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/opl-026-overseas-pharmaceuticals-epilepsy-likelihood-of-approval/ 2024-12-29T16:50:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gs-1191-gritgen-therapeutics-hemophilia-a-factor-viii-deficiency-likelihood-of-approval/ 2024-06-19T03:49:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xmab-541-xencor-peritoneal-cancer-likelihood-of-approval/ 2024-09-09T07:06:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xmab-541-xencor-metastatic-ovarian-cancer-likelihood-of-approval/ 2024-09-09T07:06:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xmab-541-xencor-fallopian-tube-cancer-likelihood-of-approval/ 2024-09-09T07:06:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xmab-541-xencor-uterine-cancer-likelihood-of-approval/ 2024-09-09T07:06:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xmab-541-xencor-endometrial-cancer-likelihood-of-approval/ 2024-09-09T07:06:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/yolt-101-yoltech-therapeutics-heterozygous-familial-hypercholesterolemia-hefh-likelihood-of-approval/ 2024-06-19T03:47:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/elvn-002-enliven-therapeutics-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-06-19T03:47:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anti-bcma-car-t-cells-eugia-pharma-specialties-refractory-multiple-myeloma-likelihood-of-approval/ 2024-06-19T03:46:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anti-bcma-car-t-cells-eugia-pharma-specialties-relapsed-multiple-myeloma-likelihood-of-approval/ 2024-06-19T03:46:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vosilasarm-ellipses-pharma-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2024-06-19T03:46:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/avibactam-tomilopil-ceftibuten-pfizer-urinary-tract-infections-likelihood-of-approval/ 2024-06-19T03:45:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mtx-463-mediar-therapeutics-fibrosis-likelihood-of-approval/ 2024-06-19T03:44:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jab-30355-jacobio-pharmaceuticals-group-solid-tumor-likelihood-of-approval/ 2024-09-09T07:06:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jab-30355-jacobio-pharmaceuticals-group-small-cell-lung-cancer-likelihood-of-approval/ 2024-09-09T07:06:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jab-30355-jacobio-pharmaceuticals-group-gastric-cancer-likelihood-of-approval/ 2024-09-09T07:06:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jab-30355-jacobio-pharmaceuticals-group-pancreatic-cancer-likelihood-of-approval/ 2024-09-09T07:06:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jab-30355-jacobio-pharmaceuticals-group-ovarian-cancer-likelihood-of-approval/ 2024-09-09T07:06:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jab-30355-jacobio-pharmaceuticals-group-breast-cancer-likelihood-of-approval/ 2024-09-09T07:06:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/radiprodil-neurvati-neurosciences-seizures-likelihood-of-approval/ 2024-12-29T16:50:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/radiprodil-neurvati-neurosciences-tuberous-sclerosis-likelihood-of-approval/ 2024-12-29T16:50:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nono-42-nono-acute-ischemic-stroke-likelihood-of-approval/ 2024-12-29T16:50:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sanfetrinem-cilexetil-gsk-tuberculosis-likelihood-of-approval/ 2024-06-19T03:41:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ibi-343-innovent-biologics-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2024-12-29T16:50:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ibi-343-innovent-biologics-solid-tumor-likelihood-of-approval-2/ 2024-12-29T16:49:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azd-7798-astrazeneca-crohn-s-disease-regional-enteritis-likelihood-of-approval/ 2024-12-29T16:50:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jnj-80038114-johnson-johnson-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2024-06-19T03:39:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/typhoid-bivalent-vaccine-serum-institute-of-india-paratyphoid-fever-likelihood-of-approval/ 2024-12-29T16:50:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/typhoid-bivalent-vaccine-serum-institute-of-india-typhoid-fever-likelihood-of-approval/ 2025-01-23T02:28:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jnj-8543-johnson-johnson-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2025-01-23T02:28:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/d3l-001-d3-bio-human-epidermal-growth-factor-receptor-2-positive-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2025-01-23T02:28:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/d3l-001-d3-bio-gastroesophageal-ge-junction-carcinomas-likelihood-of-approval/ 2025-01-23T02:28:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/d3l-001-d3-bio-gastric-cancer-likelihood-of-approval/ 2025-01-23T02:28:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/des-7114-eli-lilly-and-co-ulcerative-colitis-likelihood-of-approval/ 2024-06-19T03:37:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tng-462-tango-therapeutics-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2024-09-09T07:06:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tng-462-tango-therapeutics-soft-tissue-sarcoma-likelihood-of-approval/ 2024-09-09T07:06:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/donepezil-inventage-lab-alzheimer-s-disease-likelihood-of-approval/ 2025-01-23T02:28:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vcar33allo-vor-biopharma-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2024-06-19T03:34:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vcar33allo-vor-biopharma-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2024-06-19T03:34:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bis-5-l-l-biopharma-endometrial-cancer-likelihood-of-approval/ 2025-01-23T02:28:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bis-5-l-l-biopharma-solid-tumor-likelihood-of-approval/ 2025-01-23T02:28:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ibi-363-innovent-biologics-solid-tumor-likelihood-of-approval/ 2025-01-23T02:28:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/chm-0201-chimeric-therapeutics-myelodysplastic-syndrome-likelihood-of-approval/ 2024-06-19T03:30:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/prax-628-praxis-precision-medicines-epilepsy-likelihood-of-approval/ 2025-01-23T02:28:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tqh-2722-chia-tai-tianqing-pharmaceutical-group-nasal-polyps-nasal-polyposis-likelihood-of-approval/ 2024-07-06T05:22:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tqh-2722-chia-tai-tianqing-pharmaceutical-group-sinusitis-likelihood-of-approval/ 2024-06-19T03:29:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/influenza-quadrivalent-split-virion-vaccine-changchun-institute-of-biological-products-influenza-a-virus-h3n2-subtype-infections-likelihood-of-approval/ 2024-06-19T03:29:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/influenza-quadrivalent-split-virion-vaccine-changchun-institute-of-biological-products-influenzavirus-b-infections-likelihood-of-approval/ 2024-06-19T03:29:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/influenza-quadrivalent-split-virion-vaccine-changchun-institute-of-biological-products-influenza-a-virus-h1n1-subtype-infections-likelihood-of-approval/ 2024-06-19T03:28:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lm-108-lanova-medicines-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2025-01-23T02:28:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/scg-101-scg-cell-therapy-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2025-01-23T02:28:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/glk-302-glaukos-presbyopia-likelihood-of-approval/ 2024-06-19T03:27:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mrt-2359-monte-rosa-therapeutics-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2025-01-23T02:28:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ysch-01-shanghai-yuansong-biotechnology-solid-tumor-likelihood-of-approval/ 2024-06-19T03:26:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kyv-101-kyverna-therapeutics-primary-progressive-multiple-sclerosis-ppms-likelihood-of-approval/ 2025-01-23T02:28:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kyv-101-kyverna-therapeutics-secondary-progressive-multiple-sclerosis-spms-likelihood-of-approval/ 2025-01-23T02:28:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kyv-101-kyverna-therapeutics-myasthenia-gravis-likelihood-of-approval/ 2025-01-23T02:28:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/thiostrepton-rs-oncology-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-23T02:27:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/biogam-microgen-idiopathic-thrombocytopenic-purpura-immune-thrombocytopenic-purpura-likelihood-of-approval/ 2025-01-23T02:27:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mytx-011-mythic-therapeutics-squamous-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-09-09T07:05:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rgt-075-qilu-regor-therapeutics-obesity-likelihood-of-approval/ 2024-06-19T03:24:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sir-2446-sironax-multiple-sclerosis-likelihood-of-approval/ 2024-06-19T03:24:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sir-2446-sironax-alzheimer-s-disease-likelihood-of-approval/ 2024-06-19T03:24:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aflibercept-biosimilar-alvotech-wet-neovascular-exudative-macular-degeneration-likelihood-of-approval/ 2025-01-23T02:27:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lysergic-acid-diethylamide-mindbio-therapeutics-major-depressive-disorder-likelihood-of-approval/ 2025-01-23T02:27:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lysergic-acid-diethylamide-mindbio-therapeutics-anxiety-disorders-likelihood-of-approval/ 2025-01-23T02:27:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/betamethasone-dipropionate-oticara-rhinosinusitis-likelihood-of-approval/ 2025-01-23T02:27:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lctb-21-perha-pharmaceuticals-down-syndrome-likelihood-of-approval/ 2024-07-06T05:22:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lctb-21-perha-pharmaceuticals-alzheimer-s-disease-likelihood-of-approval/ 2024-07-06T05:22:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kn-056-alphamab-oncology-type-2-diabetes-likelihood-of-approval/ 2025-01-23T02:27:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/denosumab-biosimilar-alvotech-post-menopausal-osteoporosis-likelihood-of-approval/ 2025-01-23T02:27:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gsk-4024484-gsk-malaria-likelihood-of-approval/ 2024-06-19T03:19:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dzd-8586-dizal-pharmaceutical-follicular-lymphoma-likelihood-of-approval/ 2025-01-23T02:27:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hc-7366-hibercell-metastatic-renal-cell-carcinoma-likelihood-of-approval/ 2024-07-06T05:22:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ima-203cd8-immatics-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval-2/ 2024-12-29T14:53:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pembrolizumab-vibostolimab-merck-metastatic-renal-cell-carcinoma-likelihood-of-approval/ 2025-01-23T02:27:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/favezelimab-pembrolizumab-merck-esophageal-cancer-likelihood-of-approval/ 2024-06-19T03:16:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cst-2032-nadolol-curasen-therapeutics-dementia-associated-with-alzheimer-s-disease-likelihood-of-approval/ 2024-06-19T03:15:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cst-2032-nadolol-curasen-therapeutics-mild-cognitive-impairment-likelihood-of-approval/ 2024-06-19T03:15:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gm-60106-jd-bioscience-fibrosis-likelihood-of-approval/ 2025-01-23T02:27:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/okl-1111-alveron-pharma-brain-hemorrhage-likelihood-of-approval/ 2024-06-19T03:11:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brexanolone-neutherapeutics-parkinson-s-disease-likelihood-of-approval/ 2024-06-19T03:10:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tcr-1672-sino-biopharmaceutical-endometriosis-likelihood-of-approval/ 2024-07-06T05:21:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tcr-1672-sino-biopharmaceutical-asthma-likelihood-of-approval/ 2024-07-06T05:21:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/177lu-pnt6555-eli-lilly-and-co-esophageal-squamous-cell-carcinoma-escc-likelihood-of-approval/ 2025-01-23T02:27:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/177lu-pnt6555-eli-lilly-and-co-metastatic-adenocarcinoma-of-the-pancreas-likelihood-of-approval/ 2025-01-23T02:27:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/177lu-pnt6555-eli-lilly-and-co-metastatic-colorectal-cancer-likelihood-of-approval/ 2025-01-23T02:27:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/177lu-pnt6555-eli-lilly-and-co-soft-tissue-sarcoma-likelihood-of-approval/ 2025-01-23T02:26:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/177lu-pnt6555-eli-lilly-and-co-solid-tumor-likelihood-of-approval/ 2025-01-23T02:26:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/177lu-pnt6555-eli-lilly-and-co-metastatic-melanoma-likelihood-of-approval/ 2025-01-23T02:26:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ac-0676-accutar-biotechnology-follicular-lymphoma-likelihood-of-approval/ 2025-01-23T02:26:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gm-2505-gilgamesh-pharmaceuticals-major-depressive-disorder-likelihood-of-approval/ 2025-01-23T02:26:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gm-2505-gilgamesh-pharmaceuticals-anxiety-disorders-likelihood-of-approval/ 2025-01-23T02:26:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/opzelura-incyte-vulvar-lichen-sclerosus-likelihood-of-approval/ 2025-01-23T02:26:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/opzelura-incyte-seborrhea-likelihood-of-approval/ 2025-01-23T02:26:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/opzelura-incyte-hidradenitis-suppurativa-likelihood-of-approval/ 2025-01-23T02:26:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/opzelura-incyte-hand-dermatitis-likelihood-of-approval/ 2025-01-23T02:26:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gs-0151-gilead-sciences-rheumatoid-arthritis-likelihood-of-approval/ 2025-01-23T02:26:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/etx-19477-858-therapeutics-solid-tumor-likelihood-of-approval/ 2024-06-19T03:05:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tt-01488-transthera-sciences-nanjing-follicular-lymphoma-likelihood-of-approval/ 2024-06-19T03:04:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tqb-2868-chia-tai-tianqing-pharmaceutical-group-metastatic-pancreatic-cancer-likelihood-of-approval/ 2024-09-09T07:04:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mrna-1365-moderna-respiratory-syncytial-virus-rsv-infections-likelihood-of-approval/ 2024-07-06T05:21:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pm-1015-biotheus-solid-tumor-likelihood-of-approval/ 2024-06-19T03:03:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gcc19cart-innovative-cellular-therapeutics-metastatic-colorectal-cancer-likelihood-of-approval/ 2025-01-23T02:26:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gt-201-shanghai-grit-biotechnology-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-23T02:26:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jnj-9414-johnson-johnson-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2024-06-19T03:02:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/oricar-017-oricell-therapeutics-shanghai-refractory-multiple-myeloma-likelihood-of-approval/ 2025-01-23T02:26:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/oricar-017-oricell-therapeutics-shanghai-relapsed-multiple-myeloma-likelihood-of-approval/ 2025-01-23T02:19:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgb-16673-beigene-follicular-lymphoma-likelihood-of-approval/ 2025-01-23T02:19:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lm-302-bristol-myers-squibb-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2025-01-23T02:19:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rp-12146-rhizen-pharmaceuticals-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2024-07-06T05:21:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rp-12146-rhizen-pharmaceuticals-peritoneal-cancer-likelihood-of-approval/ 2024-07-06T05:21:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rp-12146-rhizen-pharmaceuticals-fallopian-tube-cancer-likelihood-of-approval/ 2024-07-06T05:21:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rp-12146-rhizen-pharmaceuticals-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2024-07-06T05:21:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rp-12146-rhizen-pharmaceuticals-endometrial-cancer-likelihood-of-approval/ 2024-07-06T05:21:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rp-12146-rhizen-pharmaceuticals-solid-tumor-likelihood-of-approval/ 2024-07-06T05:21:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rp-12146-rhizen-pharmaceuticals-small-cell-lung-cancer-likelihood-of-approval/ 2024-07-06T05:21:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rp-12146-rhizen-pharmaceuticals-gastric-cancer-likelihood-of-approval/ 2024-07-06T05:21:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rp-12146-rhizen-pharmaceuticals-pancreatic-cancer-likelihood-of-approval/ 2024-07-06T05:21:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rp-12146-rhizen-pharmaceuticals-colorectal-cancer-likelihood-of-approval/ 2024-07-06T05:21:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rp-12146-rhizen-pharmaceuticals-ovarian-cancer-likelihood-of-approval/ 2024-07-06T05:20:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rp-12146-rhizen-pharmaceuticals-breast-cancer-likelihood-of-approval/ 2024-07-06T05:20:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/can-1012-sr-canwell-pharma-solid-tumor-likelihood-of-approval/ 2025-01-23T02:19:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pembrolizumab-quavonlimab-merck-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-23T02:19:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/apg-777-apogee-therapeutics-atopic-dermatitis-atopic-eczema-likelihood-of-approval/ 2024-07-06T05:20:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lx-2020-lexeo-therapeutics-cardiomyopathy-likelihood-of-approval/ 2024-06-19T02:56:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hs-20093-gsk-solid-tumor-likelihood-of-approval/ 2025-01-23T02:19:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gsk-3888130-gsk-multiple-sclerosis-likelihood-of-approval/ 2024-06-19T10:35:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/blm-07d1-systimmune-metastatic-transitional-urothelial-tract-cancer-likelihood-of-approval/ 2025-01-23T02:18:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/blm-07d1-systimmune-metastatic-ovarian-cancer-likelihood-of-approval/ 2025-01-23T02:18:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/blm-07d1-systimmune-endometrial-cancer-likelihood-of-approval/ 2025-01-23T02:18:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/blm-07d1-systimmune-cervical-cancer-likelihood-of-approval/ 2025-01-23T02:18:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xnw-5004-evopoint-bioscience-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2024-07-06T05:20:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xnw-5004-evopoint-bioscience-ureter-cancer-likelihood-of-approval/ 2024-07-06T05:20:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xnw-5004-evopoint-bioscience-urethral-cancer-likelihood-of-approval/ 2024-07-06T05:20:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xnw-5004-evopoint-bioscience-transitional-cell-carcinoma-urothelial-cell-carcinoma-likelihood-of-approval/ 2024-07-06T05:20:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xnw-5004-evopoint-bioscience-nasopharyngeal-cancer-likelihood-of-approval/ 2024-07-06T05:20:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xnw-5004-evopoint-bioscience-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-07-06T05:20:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xnw-5004-evopoint-bioscience-small-cell-lung-cancer-likelihood-of-approval/ 2024-07-06T05:20:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xnw-5004-evopoint-bioscience-cervical-cancer-likelihood-of-approval/ 2024-07-06T05:20:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lb-2102-novartis-small-cell-lung-cancer-likelihood-of-approval/ 2024-06-19T02:51:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/a-400-ellipses-pharma-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-23T02:18:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cbp-1018-coherent-biopharma-bone-metastasis-likelihood-of-approval/ 2025-01-23T02:18:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/olx-75016-olix-pharmaceuticals-liver-fibrosis-likelihood-of-approval/ 2024-07-06T05:20:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/estradiol-norethindrone-acetate-relugolix-sumitomo-pharma-america-female-contraception-likelihood-of-approval/ 2025-01-23T02:18:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jnj-8343-johnson-johnson-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2025-01-23T02:18:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cabazitaxel-zhuhai-beihai-biotech-prostate-cancer-likelihood-of-approval/ 2024-06-19T02:49:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rgv-004-hangzhou-rongu-biotechnology-primary-mediastinal-b-cell-lymphoma-likelihood-of-approval/ 2024-09-09T07:04:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rgv-004-hangzhou-rongu-biotechnology-follicular-lymphoma-likelihood-of-approval/ 2024-09-09T07:04:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rgv-004-hangzhou-rongu-biotechnology-mantle-cell-lymphoma-likelihood-of-approval/ 2024-09-09T07:04:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ank-101-ankyra-therapeutics-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-23T02:18:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cd33-nke-bristol-myers-squibb-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-23T02:18:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cd33-nke-bristol-myers-squibb-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-23T02:18:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/esketamine-hydrochloride-jiangsu-hengrui-medicine-general-anesthetic-effect-likelihood-of-approval/ 2024-06-19T02:46:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/utaa-17-persongen-biotherapeutics-suzhou-refractory-multiple-myeloma-likelihood-of-approval/ 2024-06-19T02:46:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/utaa-17-persongen-biotherapeutics-suzhou-relapsed-multiple-myeloma-likelihood-of-approval/ 2024-06-19T02:45:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/taa-05-persongen-biotherapeutics-suzhou-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2024-06-19T02:45:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/taa-05-persongen-biotherapeutics-suzhou-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2024-06-19T02:45:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lonigutamab-acelyrin-graves-ophthalmopathy-likelihood-of-approval/ 2024-06-19T02:44:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/im-101-immunabs-paroxysmal-nocturnal-hemoglobinuria-likelihood-of-approval/ 2025-01-23T02:18:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/im-101-immunabs-myasthenia-gravis-likelihood-of-approval/ 2025-01-23T02:18:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/im-101-immunabs-age-related-macular-degeneration-likelihood-of-approval/ 2025-01-23T02:18:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/im-101-immunabs-autoimmune-disorders-likelihood-of-approval/ 2025-01-23T02:17:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ustekinumab-biosimilar-biocon-crohn-s-disease-regional-enteritis-likelihood-of-approval/ 2025-01-23T02:17:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/petrelintide-zealand-pharma-obesity-likelihood-of-approval/ 2024-06-19T02:43:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/orm-5029-orum-therapeutics-human-epidermal-growth-factor-receptor-2-positive-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2025-01-23T02:17:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/orm-5029-orum-therapeutics-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval/ 2025-01-23T02:17:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/orm-5029-orum-therapeutics-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-23T02:17:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/orm-5029-orum-therapeutics-gastric-cancer-likelihood-of-approval/ 2025-01-23T02:17:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ecc-5004-astrazeneca-obesity-likelihood-of-approval/ 2025-01-23T02:17:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kt-333-kymera-therapeutics-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval-2/ 2024-12-29T14:51:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/shr-1905-gsk-asthma-likelihood-of-approval/ 2025-01-23T02:17:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/islatravir-lenacapavir-gilead-sciences-human-immunodeficiency-virus-hiv-infections-aids-likelihood-of-approval/ 2025-01-23T02:17:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pro-1184-profoundbio-suzhou-peritoneal-cancer-likelihood-of-approval/ 2024-06-19T02:39:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pro-1184-profoundbio-suzhou-fallopian-tube-cancer-likelihood-of-approval/ 2024-06-19T02:39:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/janx-007-janux-therapeutics-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2024-06-19T02:39:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cbt-009-cloudbreak-therapeutics-myopia-likelihood-of-approval/ 2025-01-23T02:17:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lp-118-newave-pharmaceutical-t-cell-acute-lymphocytic-leukemia-t-cell-acute-lymphoblastic-leukaemia-likelihood-of-approval/ 2025-01-23T02:17:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lp-118-newave-pharmaceutical-refractory-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2025-01-23T02:17:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lp-118-newave-pharmaceutical-relapsed-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2025-01-23T02:17:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lp-118-newave-pharmaceutical-waldenstrom-macroglobulinemia-lymphoplasmacytic-lymphoma-likelihood-of-approval/ 2025-01-23T02:17:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/iti-1284-intra-cellular-therapies-psychosis-likelihood-of-approval/ 2025-01-23T02:16:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/iti-1284-intra-cellular-therapies-dementia-likelihood-of-approval/ 2025-01-23T02:16:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vmt-a-net-perspective-therapeutics-neuroendocrine-gastroenteropancreatic-tumors-gep-net-likelihood-of-approval/ 2025-01-23T02:16:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cannabidiol-empowerpharm-social-anxiety-disorder-sad-social-phobia-likelihood-of-approval/ 2024-06-19T02:36:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cannabidiol-ananda-scientific-opium-opioid-addiction-likelihood-of-approval/ 2025-01-23T02:16:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/act-777991-idorsia-pharmaceutical-type-1-diabetes-juvenile-diabetes-likelihood-of-approval/ 2025-01-23T02:16:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bi-765128-boehringer-ingelheim-international-diabetic-retinopathy-likelihood-of-approval/ 2024-06-19T02:35:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lava-1207-lava-therapeutics-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2025-01-23T02:16:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zidesamtinib-nuvalent-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-23T02:16:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rmc-6236-revolution-medicines-melanoma-likelihood-of-approval/ 2025-01-23T02:16:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rmc-6236-revolution-medicines-gynecological-cancer-likelihood-of-approval/ 2025-01-23T02:16:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tidal-01-turnstone-biologics-recurrent-head-and-neck-squamous-cell-carcinoma-likelihood-of-approval/ 2025-01-23T02:16:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/iph-6501-innate-pharma-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2024-09-09T07:03:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/iph-6501-innate-pharma-thymic-carcinoma-likelihood-of-approval/ 2024-09-09T07:03:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/iph-6501-innate-pharma-b-cell-non-hodgkin-lymphoma-likelihood-of-approval/ 2024-09-09T07:03:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/iph-6501-innate-pharma-follicular-lymphoma-likelihood-of-approval/ 2024-09-09T07:02:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/iph-6501-innate-pharma-mantle-cell-lymphoma-likelihood-of-approval/ 2024-09-09T07:02:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/iph-6501-innate-pharma-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2024-09-09T07:02:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ad-218-addpharma-hyperlipidemia-likelihood-of-approval/ 2025-01-23T02:16:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hygromycin-flightpath-biosciences-lyme-disease-likelihood-of-approval/ 2025-01-23T02:16:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bcma-targeted-car-t-cells-shanghai-yake-biotechnology-refractory-multiple-myeloma-likelihood-of-approval/ 2024-06-19T02:29:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bcma-targeted-car-t-cells-shanghai-yake-biotechnology-relapsed-multiple-myeloma-likelihood-of-approval/ 2024-06-19T02:29:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imm-1-104-immuneering-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2025-01-23T02:16:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/absk-121-abbisko-therapeutics-solid-tumor-likelihood-of-approval/ 2025-01-23T02:16:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zavacorilant-corcept-therapeutics-amyotrophic-lateral-sclerosis-likelihood-of-approval/ 2024-06-19T02:28:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zavacorilant-corcept-therapeutics-huntington-disease-likelihood-of-approval/ 2024-06-19T02:28:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zavacorilant-corcept-therapeutics-alzheimer-s-disease-likelihood-of-approval/ 2024-06-19T02:27:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vrt-106-guangzhou-virotech-pharmaceutical-cervical-cancer-likelihood-of-approval/ 2025-01-23T02:16:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vt-3989-vivace-therapeutics-malignant-pleural-mesothelioma-likelihood-of-approval/ 2024-06-19T02:26:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vt-3989-vivace-therapeutics-solid-tumor-likelihood-of-approval/ 2024-06-19T02:25:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jnj-9401-johnson-johnson-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2025-01-23T02:15:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/noe-115-noema-pharma-vasomotor-symptoms-of-menopause-hot-flashes-likelihood-of-approval/ 2025-01-23T02:15:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sysa-1801-elevation-oncology-solid-tumor-likelihood-of-approval/ 2025-01-23T02:15:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sysa-1801-elevation-oncology-pancreatic-cancer-likelihood-of-approval/ 2025-01-23T02:15:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/salvianolic-acid-a-for-injection-shanghai-pharmaceutical-group-angina-angina-pectoris-likelihood-of-approval/ 2024-09-09T07:02:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ht-6184-halia-therapeutics-anemia-likelihood-of-approval/ 2025-01-23T02:15:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ht-6184-halia-therapeutics-post-operative-pain-likelihood-of-approval/ 2025-01-23T02:15:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nisotirostide-eli-lilly-and-co-obesity-likelihood-of-approval/ 2024-06-19T02:23:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cbg-002-carbiogene-therapeutics-refractory-multiple-myeloma-likelihood-of-approval/ 2025-01-23T02:15:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cbg-002-carbiogene-therapeutics-relapsed-multiple-myeloma-likelihood-of-approval/ 2025-01-23T02:15:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/obx-115-obsidian-therapeutics-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-23T02:15:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/obx-115-obsidian-therapeutics-solid-tumor-likelihood-of-approval/ 2025-01-23T02:15:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nvg-111-novalgen-follicular-lymphoma-likelihood-of-approval/ 2025-01-23T02:15:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nvg-111-novalgen-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2025-01-23T02:15:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vsj-110-vanda-pharmaceuticals-keratoconjunctivitis-sicca-dry-eye-likelihood-of-approval/ 2025-01-23T02:15:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sm-020-dermbiont-squamous-cell-carcinoma-likelihood-of-approval/ 2025-01-23T02:15:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sm-020-dermbiont-basal-cell-carcinoma-basal-cell-epithelioma-likelihood-of-approval/ 2025-01-23T02:15:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ik-595-ikena-oncology-nerve-sheath-tumor-likelihood-of-approval/ 2024-06-19T02:20:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ik-595-ikena-oncology-thyroid-cancer-likelihood-of-approval/ 2024-06-19T02:19:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ik-595-ikena-oncology-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-06-19T02:19:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ik-595-ikena-oncology-glioma-likelihood-of-approval/ 2024-06-19T02:19:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ik-595-ikena-oncology-pancreatic-cancer-likelihood-of-approval/ 2024-06-19T02:19:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ik-595-ikena-oncology-melanoma-likelihood-of-approval/ 2024-06-19T02:18:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ik-595-ikena-oncology-colorectal-cancer-likelihood-of-approval/ 2024-06-19T02:18:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ik-595-ikena-oncology-breast-cancer-likelihood-of-approval/ 2024-06-19T02:18:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dr-0201-dren-bio-b-cell-non-hodgkin-lymphoma-likelihood-of-approval/ 2025-01-23T02:14:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gsk-3923868-gsk-asthma-likelihood-of-approval/ 2025-01-23T02:14:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/wal-0921-walden-biosciences-chronic-kidney-disease-chronic-renal-failure-likelihood-of-approval/ 2024-06-19T02:15:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eo-2002-emmecell-corneal-edema-likelihood-of-approval/ 2024-06-19T02:15:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mrna-3705-moderna-methylmalonic-acidemia-likelihood-of-approval/ 2024-06-19T02:15:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tsc-201-hla-b-07-02-tscan-therapeutics-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-23T02:14:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tsc-201-hla-b-07-02-tscan-therapeutics-anal-cancer-likelihood-of-approval/ 2025-01-23T02:14:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tsc-201-hla-b-07-02-tscan-therapeutics-head-and-neck-cancer-likelihood-of-approval/ 2025-01-23T02:14:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tsc-201-hla-b-07-02-tscan-therapeutics-melanoma-likelihood-of-approval/ 2025-01-23T02:14:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tsc-201-hla-b-07-02-tscan-therapeutics-cervical-cancer-likelihood-of-approval/ 2025-01-23T02:14:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tsc-201-hla-b-07-02-tscan-therapeutics-ovarian-cancer-likelihood-of-approval/ 2025-01-23T02:14:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/oncarlytics-imugene-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2025-01-23T02:14:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pnt-2001-eli-lilly-and-co-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2025-01-23T02:14:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rg-6315-genentech-usa-fibrosis-likelihood-of-approval/ 2025-01-23T02:14:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/denosumab-biosimilar-celltrion-osteoporosis-likelihood-of-approval-2/ 2024-12-29T14:48:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ludotadipep-futurechem-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2025-01-23T02:14:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kp-201-korea-pharma-gastric-ulcers-likelihood-of-approval/ 2025-01-23T02:14:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/muvalaplin-eli-lilly-and-co-atherosclerosis-likelihood-of-approval/ 2024-06-19T01:58:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nm-32-numab-therapeutics-solid-tumor-likelihood-of-approval/ 2024-06-19T01:58:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sot-201-sotio-biotech-solid-tumor-likelihood-of-approval/ 2024-07-06T05:18:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/evt-894-evotec-chikungunya-fever-likelihood-of-approval/ 2025-01-23T02:13:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/divarasib-genentech-usa-solid-tumor-likelihood-of-approval/ 2025-01-23T02:13:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/divarasib-genentech-usa-pancreatic-cancer-likelihood-of-approval/ 2025-01-23T02:13:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/emb-07-epimab-biotherapeutics-mantle-cell-lymphoma-likelihood-of-approval/ 2024-09-09T07:01:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/emb-07-epimab-biotherapeutics-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2024-09-09T07:01:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/emb-07-epimab-biotherapeutics-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2024-09-09T07:01:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/osivelotor-pfizer-sickle-cell-disease-likelihood-of-approval/ 2025-01-23T02:13:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dalmitamig-regeneron-pharmaceuticals-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2025-01-23T02:13:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trastuzumab-rezetecan-jiangsu-hengrui-medicine-gastroesophageal-ge-junction-carcinomas-likelihood-of-approval/ 2025-01-23T02:13:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trastuzumab-rezetecan-jiangsu-hengrui-medicine-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-23T02:13:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sodium-nitrite-thirty-respiratory-cystic-fibrosis-likelihood-of-approval/ 2025-01-23T02:13:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lasn-01-lassen-therapeutics-1-interstitial-lung-diseases-diffuse-parenchymal-lung-disease-likelihood-of-approval/ 2024-06-19T01:51:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lasn-01-lassen-therapeutics-1-idiopathic-pulmonary-fibrosis-likelihood-of-approval/ 2024-06-19T01:50:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bi-764524-boehringer-ingelheim-international-proliferative-diabetic-retinopathy-pdr-likelihood-of-approval/ 2024-07-06T05:17:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tl-895-telios-pharma-systemic-mastocytosis-likelihood-of-approval/ 2025-01-23T02:13:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cln-978-cullinan-therapeutics-follicular-lymphoma-likelihood-of-approval/ 2024-06-19T01:49:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cln-978-cullinan-therapeutics-mantle-cell-lymphoma-likelihood-of-approval/ 2024-06-19T01:49:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jnj-8902-johnson-johnson-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2024-06-19T01:48:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cardiamp-biocardia-myocardial-ischemia-likelihood-of-approval/ 2024-06-19T01:48:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cc-98633-bristol-myers-squibb-refractory-multiple-myeloma-likelihood-of-approval/ 2024-06-19T01:48:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cc-98633-bristol-myers-squibb-relapsed-multiple-myeloma-likelihood-of-approval/ 2024-06-19T01:47:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rlyb-116-rallybio-paroxysmal-nocturnal-hemoglobinuria-likelihood-of-approval/ 2025-01-23T02:13:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rlyb-116-rallybio-myasthenia-gravis-likelihood-of-approval/ 2025-01-23T02:13:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sigvotatug-vedotin-pfizer-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2025-01-23T02:13:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sigvotatug-vedotin-pfizer-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval/ 2025-01-23T02:13:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sigvotatug-vedotin-pfizer-squamous-cell-carcinoma-likelihood-of-approval/ 2025-01-23T02:13:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sigvotatug-vedotin-pfizer-bladder-cancer-likelihood-of-approval/ 2025-01-23T02:13:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sigvotatug-vedotin-pfizer-gastric-cancer-likelihood-of-approval/ 2025-01-23T02:12:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sigvotatug-vedotin-pfizer-cervical-cancer-likelihood-of-approval/ 2025-01-23T02:12:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sigvotatug-vedotin-pfizer-ovarian-cancer-likelihood-of-approval/ 2025-01-23T02:12:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tofacitinib-citrate-twi-biotechnology-dermatological-disorders-likelihood-of-approval/ 2025-01-23T02:12:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rabi-767-lamassu-pharma-pancreatitis-likelihood-of-approval/ 2024-06-19T01:44:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cd-388-cidara-therapeutics-pandemic-influenza-likelihood-of-approval/ 2025-01-23T02:12:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cd-388-cidara-therapeutics-seasonal-influenza-likelihood-of-approval/ 2025-01-23T02:12:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cd-388-cidara-therapeutics-influenzavirus-b-infections-likelihood-of-approval/ 2025-01-23T02:12:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cd-388-cidara-therapeutics-influenzavirus-a-infections-likelihood-of-approval/ 2025-01-23T02:12:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/agent-797-mink-therapeutics-acute-respiratory-distress-syndrome-likelihood-of-approval/ 2025-01-23T02:12:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/agent-797-mink-therapeutics-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2025-01-23T02:12:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ab-001-agastiya-biotech-gallbladder-cancer-likelihood-of-approval/ 2025-01-23T02:12:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rg-6115-f-hoffmann-la-roche-gallbladder-cancer-likelihood-of-approval/ 2024-07-06T05:17:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgc-0228-brightgene-bio-medical-technology-epithelial-ovarian-cancer-likelihood-of-approval/ 2025-01-23T02:12:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgc-0228-brightgene-bio-medical-technology-non-small-cell-lung-cancer-likelihood-of-approval-2/ 2025-01-22T17:34:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgc-0228-brightgene-bio-medical-technology-breast-cancer-likelihood-of-approval/ 2025-01-23T02:12:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rhenium-186re-obisbemeda-plus-therapeutics-recurrent-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-07-06T05:16:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pembrolizumab-biosimilar-biocad-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-06-19T01:32:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pembrolizumab-biosimilar-biocad-solid-tumor-likelihood-of-approval/ 2024-06-19T01:32:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/isb-1442-ichnos-sciences-refractory-multiple-myeloma-likelihood-of-approval/ 2024-06-19T01:31:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/isb-1442-ichnos-sciences-relapsed-multiple-myeloma-likelihood-of-approval/ 2024-06-19T01:31:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mk-7602-merck-malaria-likelihood-of-approval/ 2024-06-19T01:30:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nelmastobart-stcube-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2025-01-23T02:12:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nelmastobart-stcube-head-and-neck-cancer-likelihood-of-approval/ 2025-01-23T02:11:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adp-101-alladapt-immunotherapeutics-food-allergy-likelihood-of-approval/ 2024-06-19T01:30:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cb-011-caribou-biosciences-refractory-multiple-myeloma-likelihood-of-approval/ 2024-06-19T01:29:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cb-011-caribou-biosciences-relapsed-multiple-myeloma-likelihood-of-approval/ 2024-06-19T01:29:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/asc-41-ascletis-pharma-metabolic-dysfunction-associated-steatohepatitis-mash-likelihood-of-approval/ 2024-06-19T01:29:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eo-2463-enterome-bioscience-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2024-06-19T01:28:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mrna-1189-moderna-mononucleosis-infectious-mononucleosis-glandular-fever-likelihood-of-approval/ 2024-06-19T01:28:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bb-1701-bliss-biopharmaceutical-hangzhou-human-epidermal-growth-factor-receptor-2-positive-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2025-01-23T02:11:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bb-1701-bliss-biopharmaceutical-hangzhou-gastroesophageal-ge-junction-carcinomas-likelihood-of-approval/ 2025-01-23T02:11:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bb-1701-bliss-biopharmaceutical-hangzhou-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-23T02:11:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bb-1701-bliss-biopharmaceutical-hangzhou-gastric-cancer-likelihood-of-approval/ 2025-01-23T02:11:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jnj-6420-johnson-johnson-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2024-06-19T01:26:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xmt-1660-mersana-therapeutics-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2025-01-23T02:11:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/synb-8802-synlogic-secondary-hyperoxaluria-likelihood-of-approval/ 2024-06-19T01:25:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/acd-440-alzecure-pharma-neuropathic-pain-neuralgia-likelihood-of-approval/ 2024-06-19T01:24:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/olanzapine-neurelis-schizophrenia-likelihood-of-approval/ 2024-06-19T01:24:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/msd-competes-with-pfizer-in-pneumococcal-vaccine-market-after-fda-approval/ 2024-06-18T16:49:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ability-biologics-closes-extended-18m-seed-funding-round/ 2024-06-18T16:27:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/buyers-guide/pharmaceutical-cleaning-equipment/ 2025-11-05T11:39:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/sanofi-and-belharra-forge-700m-partnership-for-immunological-diseases/ 2024-06-18T15:36:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/pyros-wins-fda-approval-for-ready-to-use-infantile-spasm-treatment/ 2024-06-18T14:59:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/the-lasting-impacts-of-the-pandemic-on-cybersecurity-in-healthcare/ 2024-06-18T14:08:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/johnson-johnson-lung-cancer-treatment/ 2024-06-18T10:12:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/qa-with-springer-natures-leslie-lansman-ethical-content-sharing-and-the-benefits-of-the-cla-pharmaceutical-licence/ 2024-06-18T10:17:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/revopsis-kemwell-biologic-development/ 2024-06-18T10:07:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/charles-river-vector-production-deal/ 2024-12-18T11:02:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-msd-keytruda/ 2024-06-18T08:26:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/can-supermarket-pharmacies-plug-urgent-healthcare-gaps/ 2024-06-13T20:48:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/olanzapine-neurelis-bipolar-disorder-manic-depression-likelihood-of-approval/ 2024-06-19T01:23:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/omalizumab-biosimilar-teva-pharmaceutical-industries-chronic-urticaria-or-hives-likelihood-of-approval/ 2024-06-18T06:59:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/olanzapine-er-teva-pharmaceutical-industries-schizophrenia-likelihood-of-approval/ 2024-09-09T07:00:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mas-825-novartis-coronary-artery-disease-cad-ischemic-heart-disease-likelihood-of-approval/ 2025-01-23T02:11:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/oct-461201-oxford-cannabinoid-technologies-visceral-pain-likelihood-of-approval/ 2025-01-23T02:11:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/oct-461201-oxford-cannabinoid-technologies-neuropathic-pain-neuralgia-likelihood-of-approval/ 2025-01-23T02:11:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/medi-0618-astrazeneca-migraine-likelihood-of-approval/ 2024-06-18T06:57:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dfv-890-novartis-coronary-artery-disease-cad-ischemic-heart-disease-likelihood-of-approval/ 2025-01-23T02:11:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/s-ketamine-afyx-therapeutics-cluster-headache-syndrome-cluster-headache-likelihood-of-approval/ 2024-06-18T06:56:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pmr-116-pimera-solid-tumor-likelihood-of-approval/ 2025-01-23T02:11:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ivb-001-vgi-health-technology-metabolic-dysfunction-associated-steatotic-liver-disease-masld-likelihood-of-approval/ 2024-06-18T06:54:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anx-009-annexon-lupus-nephritis-likelihood-of-approval/ 2024-06-18T06:54:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/knk-003-sanofi-myelodysplastic-syndrome-likelihood-of-approval/ 2024-06-18T06:53:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gene-therapy-for-cytomegalovirus-hhv-5-infections-china-immunotech-cytomegalovirus-hhv-5-infections-likelihood-of-approval/ 2024-06-18T06:53:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/molnupiravir-merck-liver-failure-hepatic-insufficiency-likelihood-of-approval/ 2025-01-23T02:11:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bi-905711-boehringer-ingelheim-international-gallbladder-cancer-likelihood-of-approval/ 2024-07-06T05:16:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/exlinkibart-lyvgen-biopharma-advanced-malignancy-likelihood-of-approval/ 2025-01-23T02:11:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hsk-21542-sichuan-haisco-pharmaceutical-post-operative-pain-likelihood-of-approval/ 2025-01-23T02:11:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/4d-150-4d-molecular-therapeutics-wet-neovascular-exudative-macular-degeneration-likelihood-of-approval/ 2025-01-23T02:11:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/4d-150-4d-molecular-therapeutics-diabetic-macular-edema-likelihood-of-approval/ 2025-01-23T02:10:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azd-0120-gracell-biotechnologies-refractory-multiple-myeloma-likelihood-of-approval/ 2025-01-23T02:10:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azd-0120-gracell-biotechnologies-relapsed-multiple-myeloma-likelihood-of-approval/ 2025-01-23T02:10:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ati-2138-aclaris-therapeutics-atopic-dermatitis-atopic-eczema-likelihood-of-approval/ 2025-01-23T02:10:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ima-402-immatics-uveal-melanoma-likelihood-of-approval/ 2025-01-23T02:10:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ima-402-immatics-synovial-sarcoma-likelihood-of-approval/ 2025-01-23T02:10:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ima-402-immatics-uterine-cancer-likelihood-of-approval/ 2025-01-23T02:10:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ima-402-immatics-solid-tumor-likelihood-of-approval/ 2025-01-23T02:10:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ima-402-immatics-ovarian-cancer-likelihood-of-approval/ 2025-01-23T02:10:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ima-402-immatics-lung-cancer-likelihood-of-approval/ 2025-01-23T02:09:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nkx-019-nkarta-b-cell-non-hodgkin-lymphoma-likelihood-of-approval/ 2025-01-23T02:09:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ranibizumab-biosimilar-generium-wet-neovascular-exudative-macular-degeneration-likelihood-of-approval/ 2024-07-06T05:15:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/acetazolamide-dronabinol-incannex-healthcare-obstructive-sleep-apnea-likelihood-of-approval/ 2024-06-18T06:45:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/wu-cart-007-wugen-lymphoblastic-lymphoma-likelihood-of-approval/ 2025-01-23T02:09:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bay-2416964-bayer-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2024-06-18T06:44:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bay-2416964-bayer-solid-tumor-likelihood-of-approval/ 2024-06-18T06:44:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/senti-202-senti-biosciences-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-23T02:09:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/senti-202-senti-biosciences-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-23T02:09:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/senti-202-senti-biosciences-myelodysplastic-syndrome-likelihood-of-approval/ 2025-01-23T02:09:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ncp-112-novacell-technology-atopic-dermatitis-atopic-eczema-likelihood-of-approval/ 2025-01-23T02:09:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/givastomig-i-mab-solid-tumor-likelihood-of-approval/ 2024-06-18T06:42:56+00:00 daily 0.2